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Abstract 
Anticancer drugs inhibit the cancer growth by killing the rapidly dividing cancer cells. 
However, anticancer drugs also kill the dividing healthy cells and cause severe damage to 
healthy tissues. More specific delivery of the cancer drugs to the cancer tissue can increase 
the drug delivery efficiency and reduce the drug’s side effects. Nanocarriers can increase 
the solubility of poorly-water soluble anticancer drugs and be modified for targeted drug 
delivery and theranostic applications. For efficient drug delivery, the drug loading 
capacity has been one of the key issues for the development of nanoparticle (NP)-based 
drug delivery systems. The biocompatible and biodegradable porous silicon (PSi) 
nanomaterial presents high drug loading capacity and tunable surface chemistry which 
renders it an ideal candidate as a drug delivery carrier. Chemical surface modification, 
which is one of the approaches to improve the nanomaterials’ properties, can lead to a 
stable nanosystem for further drug delivery applications. The main aim of this dissertation 
was to employ chemical approaches and surface modified PSi nanoparticles (NPs) to 
improve the drug delivery efficiency for potential cancer therapy applications. 
Incorporating targeting moieties to the surfaces of the nanocarriers, such as targeting 
peptides, can increase the nanocarrier’s accumulation into the cancer tissue after the 
intravenous administration. In this thesis, surface modification of amine-terminated PSi 
NPs was achieved with targeting peptides (RGDS and iRGD) via strain-promoted azide-
alkyne cycloaddition click reaction. The functionalization of the PSi NPs with the 
targeting peptides did not comprise the drug loading capacity, but enhanced the cellular 
uptake and the drug delivery efficacy of the PSi NPs in vitro. 
In addition to the targeting NP surface modifications, a multifunctional nanosystem 
was prepared with simultaneous fluorescence- and radio-labeling, and iRGD surface 
modification of the carboxylic acid-terminated PSi NPs. Both labelings were accessible 
for the in vivo biodistribution evaluation in mice by single-photon emission computed 
tomography and X-ray computed tomography, and ex vivo by immunofluorescence 
staining, respectively. The iRGD modification enhanced the tumor uptake of the PSi NPs 
after the intravenous administration. In order to reduce the plasma protein adsorption onto 
the PSi NPs, five bioactive molecules (peptides and hydrophilic anti-fouling polymers) 
were used to modify the surface of alkyne-terminated PSi NPs using copper-catalized 
click chemistry. Dextran 40 kDa modified PSi NPs presented enhanced cellular uptake 
and the least protein adsorption of all the tested NPs. 
Furthermore, the chemical conjugation of drug molecules was studied. The targeting 
peptides were successfully conjugated to antisense interleukin-6 via copper-catalyzed [3+2] 
azide-alkyne cycloaddition for targeted angiogenic anti-inflammation in cancer. Finally, 
anticancer drug methotrexate (MTX) was chemically conjugated to the cationic PSi NPs 
and demonstrated to increase the cellular uptake of MTX with up to 96 h sustained drug 
release. A hydrophobic anti-angiogenic drug, sorafenib, was also loaded to the MTX-
conjugated PSi NPs, and the dissolution rate of this drug was considerably increased.  
In conclusion, in this thesis different chemical approaches were used to 
biofunctionalize PSi NPs and to prepare drug-conjugates formulations for potential anti-
cancer applications.  
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1 Introduction 
Cancer is one of the most life-threatening diseases in humans.
1
 The sustained chronic 
proliferation of mutant cells is the most fundamental characteristic in cancer. Normal 
tissues carefully produce growth-promoting signals and regulate the cell formation, 
whereas cancer cells irregularly release the growth-promoting signals resulting in 
uncontrollable cell proliferation and development.
2
 Chemotherapy combined with local 
therapies, such as surgery or radiotherapy, have been applied as strategies to treat cancer. 
However, non-specific delivery of chemotherapeutic agents can also harm the normal 
tissues. In addition, the poor-water solubility and low cellular uptake of various cancer 
drugs are still the challenges for cancer drug delivery.
3
 
Nanotechnology can aid in cancer drug delivery by increasing the aqueous solubility of 
many drug molecules. The surface properties of the nanocarriers can be modulated to 
increase the drug delivery efficiency and specificity. For efficient drug delivery, the drug 
loading capacity has been one of the key parameters for the development of nanoparticle 
(NP)-based drug delivery systems.
4
 Porous silicon (PSi) nanomaterials are a form of the 
chemical element Si, which have nanoporous holes in the nanostructure, rendering it a 
large surface area ratio up to 800 m
2
/g, which can be used for drug loading.
5
 PSi NPs have 
a number of unique properties that make it a potential drug delivery vector, such as high 
drug loading capacity, tunable surface chemistry and structure to increase the 
biocompatibility and other biomedical properties,
6
 such as targeted drug delivery.
7
 
Amine,
8
 carboxylic acid,
5
 and aldehyde
5
 groups have been introduced to the surface of PSi 
NPs. These chemically reactive moieties can be further functionalized with other 
biomolecules to manipulate the PSi’s properties for biomedical applications, such as 
cancer therapy and imaging. 
In cancer, the various types of cells that comprise the tumor mass all carry molecular 
biomarkers that are not expressed, or are expressed at much lower levels, in healthy cells.
9
 
For example, tumor blood vessels express biomarkers that are not present in resting blood 
vessels of normal tissues, but can be shared by angiogenic vessels in non-malignant 
conditions.
10
 The ligands which can target to the biomarkers can be used to modify the 
NPs, and thus, increase the interaction of the NPs with the cancer tissue and, consequently, 
increase the intracellular drug delivery efficiency. The concept of targeted drug delivery is 
attractive because it can increase the local drug concentration and lower the systemic 
exposure.
11-12
 Small molecules, such as folic acid,
13
 various targeting peptides,
10, 14
 protein 
ligands,
15-16
 as well nucleic acid-based aptamers,
7, 17
 have been widely investigated for the 
targeted cancer drug delivery of nanocarriers. 
Functionalized NPs involve at least one step more to introduce the targeting moieties 
to the nanosystems by surface modification. Click chemistry has been developed to 
provide a simple method to couple organic molecules in high yield under mild conditions 
and high selectivity in the presence of a diverse range of functional groups.
18
 One of the 
most widely used examples of this class of very efficient chemical reactions is the copper-
catalyzed [3+2] azide-alkyne cycloaddition (CuAAC) reaction.
19-20
 Strain-promoted azide-
alkyne cycloaddition (SPAAC) click reaction avoids using copper ion, which might 
induce cell and biological toxicity, and thus, is becoming an alternative to copper 
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catalyzed click reaction.
21
 There is a great deal of interest in developing biomaterials by 
introducing biofunctional molecules via the click chemistry. Bioactive molecules, such as 
proteins, peptides, oligonucleotides and carbohydrates, have several chemical active 
groups (e.g., amine, carboxyl acid, hydroxyl, and ester). Click reactions are potentially 
useful in bioactive molecules conjugation applications, because azides and alkynes react to 
each other without disturbing extensively the molecular or cross reactions with the 
surrounding components.
18
 In addition, the triazoles are extremely stable and not toxic.
18
 
As a result of the high surface energy, NPs can associate with plasma proteins in less 
than one second when the NPs are in contact with the blood stream fluids.
22
 This is the 
first biological barrier the NPs will encounter when administered intravenously. plasma 
protein adsorption plays an important role in the NPs recognition by the immune system 
macrophages, which will clear the NPs from the bloodstream and transport them mainly to 
the liver and spleen, failing to deliver the drug to the desired site(s) in the body. High 
molecular weight polyethylene glycol (PEG) and dextran have been investigated as 
hydrophilic polymers to sheath and aid to prevent the protein adsorption in order to 
increase the blood circulation time of the NPs.
23-24
 Biodegradable PSi NPs can also be 
used as a platform to enhance the cell uptake of low permeability drugs and sustained 
release of the chemically conjugated drugs, by simultaneously co-loading poorly water-
soluble drugs with drug-conjugated PSi NPs. 
In this dissertation, different chemical approaches were explored to develop drug 
delivery systems for targeted cancer therapy potential. In particularly, the studies of this 
thesis included: (1) development of chemical methods for surface functionalization of PSi 
NPs and peptide-oligonucleotide conjugation; (2) physicochemical characterization of the 
developed drug delivery systems; (3) in vitro and in vivo evaluation of the behavior of the 
multifunctional PSi NPs; (4) identification of the effect of PSi surface chemistry on 
plasma protein adsorption; and (5) evaluation of the drug loading and release profiles 
before and after the surface modification of the PSi NPs. 
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2 Literature review 
2.1 Cancer and cancer therapy 
Cancer is a complex disease resulting from genetic mutations.
25
 It is the most common 
cause of death in Europe,
26
 and the second leading cause of death in the USA, following 
the cardiovascular diseases.
27
 Lung, prostate, and colorectal cancers are the three leading 
causes for cancer death among men, and among women the leading causes of cancer death 
are lung, breast, and colorectal cancers.
26
 The possible causes of inducing cancer in 
individuals include genetic factors, lifestyle factors, such as tobacco, diet and exercise, 
certain types of infections, and environmental exposures to different types of chemicals 
and radiation. For most of the cancers, earlier detection and treatment provide 
substantially longer survival rates.
26-27
 Currently, more efficient cancer diagnosis and 
treatment are still under development.
4
 
2.1.1 The features of cancer 
Uncontrolled proliferation of mutant cells is the first characteristics of cancer. The cells of 
normal tissues are regulated by growth-promoting signals and differentiate to tissue forms, 
while mutated cancer cells irregularly release the growth-promoted signals and continue 
the cell doubling to form a cancer tissue.
2
 
In 2001, Hanahan and Weinberg summarized six “hallmarks of cancer”,1 followed by 
additional four “hallmarks of cancer” reviewed in 2011.2 In total, the ten characteristics of 
cancer are briefly summarized here. 
1) Cancer cells can sustain the proliferative signaling. Normal tissues maintain a 
homeostasis of cell number, and thus, well-functionalized tissue architecture by 
carefully controlling the production and release of growth-promoting signals that 
instruct the cell growth and division cycle. Cancer cells can continually produce 
proliferation signals or elevate the level of receptor proteins and maintain chronic 
cell growth, typically containing intracellular tyrosine kinase domains.
28
 
2) Cancer cells can evade growth suppressors. Similar to the controlled production of 
growth signals, there is a certain amount of antiproliferative signals operating 
within the normal tissue. However, in cancer cells dozens of tumor suppressors 
that control cell growth and proliferation have been discovered undergoing 
inactivation to tumor growth. Cancer cells can present powerful programs that 
evade the negative regulation of cell proliferation. The two prototypical tumor 
suppressors encode the retinoblastoma-associated and TP53 proteins.
29
 
3) Cancer cells can resist to cell death. The programmed cell death by apoptosis is a 
natural barrier for cancer development. However, tumor cells have a variety of 
strategies to limit or circumvent apoptosis. The most common reason for this is the 
defunctionalization of TP53 tumor suppressor.
30
 
4 
 
4) Cancer cells enable replicative immortality. The differentiated healthy cells have 
limited cycles of growth-and-division, while cancer cells have unlimited 
replicative potential.
31
 
5) Cancer cells can induce angiogenesis. Like normal tissues, tumor mass requires 
supplying of nutrients and oxygen as well as evacuating metabolic wastes and 
carbon dioxide. During tumor development, neovasculature is activated and sprout 
new vessels to help sustain the tumor mass increase.
32
 
6) Cancer cells can activate invasion and metastasis. During the development of 
cancer, sooner or later, tumor cells start to move out, invading adjacent tissues to 
get more nutrients and space. Cancer metastasis is the cause of 90% of human 
cancer deaths.
33
 
7) Genome instability and mutation in cancer. In the case of tumorgenesis, cancer 
cells often increase the rate of mutation, as well as the genome 
maintenance/repairing systems lose their functions during the tumor progression.
34
 
8) Cancer cells can induce tumor-promoting inflammation. Inflammation can supply 
bioactive molecules to the tumor microenvironment, such as growth factors that 
sustain the proliferative signaling, survival factors that limit the cell death, and 
proangiogenic factors and extracellular matrix-modifying enzymes that facilitate 
angiogenesis, invasion, and metastasis.
35
 
9) Cancer cells can reprogram energy metabolism. Even cancer cells must compensate 
for the ca. 18-fold lower efficiency of ATP production afforded by glycolysis 
related to mitochondrial oxidative phosphorylation. In order to fuel cell growth and 
division, cancer cells up-regulate glucose transporters to substantially increase the 
glucose import into the cytoplasm.
36
 
10) Cancer cells can evade immune destruction. Clinical cases have revealed the 
existence of anti-tumoral immune responses in some forms of human cancer. 
However, highly immunogenic cancer cells can evade immune destruction by 
disabling components of the immune system that have been dispatched to eliminate 
them.
37
 
 
As a result of the discovery of the cancer characteristics, the mechanism-based targeted 
cancer therapy of the drug delivery systems are under development. Figure 1 summarizes 
the hallmarks of cancer and the possible therapeutic approaches.
2
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Figure 1. The hallmarks and therapeutic targeting in cancer treatment. Copyright © (2011) 
CellPress. Reprinted with permission from ref. 
2
. 
2.1.2 Clinical cancer treatments 
Clinical cancer treatments include surgery, chemotherapy, radiotherapy, targeted therapy 
and immunotherapy.
25
 Surgery is mainly used to remove the solid tumor mass. 
Chemotherapy is the approach of treating cancer with cytostatic drugs which can kill the 
rapidly dividing cancer cells, often by disturbing the DNA duplication.
38
 Thus, 
chemotherapeutic reagents need to be delivered into the cancer cells. However, 
chemotherapy also kills the dividing healthy cells. Radiotherapy is based on the decay of 
radionuclides to release the x-rays or -rays to damage the localized area and to stop the 
cancer cells from growing or dividing. The radiation can be delivered by external beam 
radiation, or local implantation or system administration of radioactive agents.
39
 
Radiotherapy can be used to treat almost all types of cancer. Radiotherapy induces side 
effects to the nearby tissues and organs. Different from chemotherapy and radiotherapy, 
targeted therapies generally involve the pharmaceutically active agents to specifically 
interact with the proteins related to cancer development and inhibit the tumor growth.
2
 
Targeted therapies aim to achieve more specific tumor treatment and reduce the side-
effects. For example, antiangiogenic drugs specifically inhibit the tumor neovasculature 
and inhibit tumor growth.
40
 Targeted therapies also include the targeting cargos mediated 
specific delivery of radionuclides or chemotherapeutical agents to the cancer site and 
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minimize the exposure to the healthy tissue.
10
 Cancer immunotherapy is another set of 
therapeutic strategies designed to fight against the cancer by stimulating the patient’s own 
immune system.
41
 In practice, one patient can be treated with a combination of several 
treatments to increase effectiveness, precision, survivability, and the quality of the 
patient’s life. Surgery is often combined with chemotherapy and/or radiotherapy. 
Chemotherapeutical and targeted therapeutic agents can be co-delivered in a form of 
combination therapy. 
Figure 1 lists the cancer treatment targets that the drugs can interfere with each of the 
acquired hallmarks necessary for the tumor growth and progression.
2
 Understanding the 
principle of cancer and mechanism-based targeted therapies can direct the cancer drug 
development. Commonly drug molecules are targeted to one or several specific receptors 
to inhibit signaling pathways, which may not be enough to completely stop the whole 
hallmark capability or the tumor growth. An unstable gene mutation in the cancer cells 
induces signaling pathway remodeling that can reset the tumor growth capability.
42
 For 
example, antiangiogenic therapies have been expected to starve the tumor growth leading 
to tumor dissolution.
43-44
 However, the clinical results showed that antiangiogenic agents 
treatment did not achieve the fantastic effect as they were expected.
45
 Another concern is 
the tumor resistance due to overcompensation from the parallel signaling pathways and 
side effects to the normal vasculature.
46
 Multidrug resistance has been rising as a problem 
resulting from the chemotherapy.
47
 The mechanisms for multidrug resistance include 
increasing the expression of drug efflux or elevated anti-apoptotic pathways due to the 
mutations and metastases of tumor cells.
47
 Delivering simultaneously more than one 
cancer drug molecule to inhibit several cancer hallmarks at the same time can increase the 
chance to inhibit the tumor growth. Chemotherapeutic agents have been co-delivered with 
small interference RNA (siRNA) against multidrug resistance proteins for cancer 
treatment.
48
 Chemotherapeutic agents can be delivered at the same time as the 
antiangiogenic drugs for combination therapy.
49
 
2.1.3 Nanomedicines for cancer treatment in clinics 
Highly effective chemotherapeutic agents often present poor water solubility or low 
permeability across biological barriers.
4
 Nanomedicines have been intensively 
investigated to increase the solubility of antineoplastic drugs in the past decades. The 
definition of a nanomedicine is the application of nanotechnology in the medical field.
3
 
There are several advantages of nanomaterials used for biomedical applications,
50
 such as: 
(1) the nanostructure can increase the solubility and stability of the chemotherapeutic 
agents in physiological conditions; (2) the NPs can carry a group of nanosized drugs 
composed of thousands of molecules as a unit in a small location, and thus, high 
therapeutic effect; (3) nanomaterials can be functionalized with biomolecules to enable 
them for targeting into specific organelles or certain tissues to increase the drug delivery 
efficacy and to reduce the side effects; (4) nanocarriers can be co-loaded with more than 
one drug into one single nanocarrier for combination therapy; (5) the NPs can be loaded 
with both drugs and imaging agents for simultaneous therapy and diagnosis or imaging to 
follow-up the biofate of the NPs. Systemic chemotherapeutic drug administration is one of 
7 
 
the few treatments for metastase stages of cancer. Among the various treatments for 
cancer therapy, eight nanomedicine-based formulations have been approved for clinical 
use (Table 1) and many other formulations are under clinical trials.
3
 
Doxil

 is a PEGylated liposome formulation loaded with doxorubicin in the aqueous 
core and has long blood circulation time (half-life of 2–3 days).51-52 The mean size of 
Doxil is in the range of 80–90 nm. Doxil has substantially higher efficacy and significant 
lower cardiotoxicity than the free drug. However, the two most severe side effects of 
Doxil are mucositis and palmar plantar erythrodysesthesia.
53
 Myocet

 is a liposomal 
doxorubicin formulation, the same as Doxil
 
except the PEGylation, with a particle size of 
ca. 190 nm.
54
 The blood circulation half-life of Myocet

 is ca. 2.5 h. Compared to Doxil

, 
Myocet

 is not associated with palmar plantar erythrodysesthesia and significantly 
reduced incidence of mucositis. Myocet

 has similar efficacy and lower cardiac-related 
toxicity than free doxorubicin.
55
 Daunoxome

 is a liposome formulation encapsulated 
with daunorubicin, which lacks a hydroxyl group at the 14-position of doxorubicin, but 
has better aqueous stability compared to doxorubicin.
56
 The particle size is ca. 50 nm and 
the circulation half-life is 2 to 4 h.
57
 The clinical results have showed higher drug 
accumulation in the tumor for the Daunoxome

 than for the free daunorubicin. The 
clinical efficacy for various forms of leukemia is active.
57
 Abraxane

 is a nanoscale 
albumin-bound formulation of paclitaxel with size ca. 100 nm.
58
 Abraxane

 has 
dramatically decreased the toxicity of the traditional paclitaxel formulations and increased 
the efficacy of the drug in clinical trials involving patients with an advanced breast cancer. 
Albumin can actively bind to endothelial glycoprotein receptor gp60 and secrete the 
protein acid and rich in cysteine, which is overexpressed in the extracellular space for a 
variety of cancers.
59
 Rexin-G

 is a cancer collagen matrix targeted liposome platform 
loaded with microRNA targeting retrovector encoding an N-terminal deletion mutant of 
the cyclin G1 gene for antineoplastic activity.
60
 Rexin-G

 is the first gene therapy 
nanomedicine for cancer treatment on the market. Oncaspar

 is a formulation of 
asparaginase covalently conjugated by PEG to prolong its circulation and retention time, 
decreasing proteolysis and renal excretion.
61
 PEGylation also shields antigenic 
determinants from immune detections, and thus, reduce the side effects of the native 
asparaginase, such as hypersensitivity.
62
 Oncaspar

 was approved as the first-line 
treatment for acute lymphoblastic leukemia as a component of a multiagent thermotherapy 
regimen by the Food and Drug Administration (FDA) in 2006.
63
 
Beyond the nanomedicines for cancer therapy, there are two nanotechnology-based 
systems for diagnostics approved for clinical applications (Table 1).
3
 Both two 
formulations are superparamagnetic iron oxide NPs (SPIONs) coated with dextran, acting 
as magnetic resonance imaging agents for the diagnostic of liver lesions.
64
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Table 1: Nanomedicines approved by one or more regulatory bodies. Copyright © (2013) 
Hindawi. Adapted with permission from ref. 
3
. 
Product/ Company Nanoplatform/API Indication Status 
Doxil / Ortho 
Biotech  
PEGylate 
liposome/doxorubicin 
Ovarian cancer Approved by FDA in 
1995  
Myocet / 
Sopherion 
Therapeutics (North 
American) and 
Cephalon Inc. 
(Europe) 
Non-PEGylated 
liposomal/doxorubici 
Metastatic breast 
cancer 
Approved in Europe in 
2000 and in Canada in 
2001 
DaunoXome/ 
Galen Ltd. 
Lipid 
encapsulation/dauno
rubicin 
Advanced HIV-
associated Kaposi’s 
sarcoma 
Approved by FDA in 
1996 
Abraxane/ 
Abraxis Bioscience 
Nanoparticulate 
albumin/paclitaxel 
Breast, lung, and 
pancreatic cancers 
Approved by FDA in 
2013 
Rexin-G/ Epeius 
Biotecnologies 
Targeting protein 
tagged phospholipid/ 
microRNA-122 
Sarcoma, osteo-
sarcoma, pancreatic 
cancer, and other solid 
tumor 
Approved in Philippine 
in 2007, and approved by 
FDA for clinical trials 
phase III in 2011 
Oncaspar/ 
Enzon Phar-
maceuticals 
PEGylated 
asparaginase 
Acute lympho-
blastic leukemia 
Approved by FDA in 
2006 
Resovist/ Bayer 
Schering Pharma 
AG 
Iron oxide NPs 
coated with 
carboxydextran 
Liver lesion 
imaging 
Approved in Europe in 
2001 
Feridex/ Berlex 
Laboratories (USA) 
and Endorem/ 
Guerbet (Europe) 
Iron oxide NPs 
coated with dextran 
Liver lesion 
imaging 
Approved by FDA and 
in Europe in 1996  
2.1.4 Nanomaterials in pre-clinical studies for cancer therapy 
In addition to the nanomedicine formulations used in the market, there are diverse types of 
nanotechnology-based drug delivery systems under pre-clinical and clinical research for 
cancer diagnosis and therapy. The nanosystems under pre-clinical research include organic 
and inorganic nanomaterials, as well as organic–inorganic hybrid nanomaterials.50, 65-66 
Based on the composition used to prepare the nanosystems, the commonly investigated 
nanomaterials can be divided into lipid-based nanosystems, polymeric NP platforms, 
protein-based drug delivery systems, and inorganic nanosystems (e.g., gold NPs, 
mesoporous silica and silicon NPs, magnetic NPs, quantum dots, and single/multiwall 
carbon nanotubes) (Figure 2). The composition of the nanomaterials, as well as the size, 
charge, and shape are the key parameters determining the in vivo fate of the nanovectors, 
the drug delivery potential, and the therapeutical efficacy.
67
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Figure 2. Schematic illustration of the representative NP platforms that have been synthesized for 
drug delivery purposes in cancer therapy. Copyright © (2013) Elsevier B.V. Adapted 
with permission from ref. 
65
. 
Lipid-based nanomaterials have contributed with the highest amount of formulations in 
pre-clinical studies, which have also led to many products entering the clinics.
3
 Liposomes, 
which are bilayered structures made of phospholipids, are the most widely studied 
nanomaterials for drug delivery due to their benign biological behavior, such as good 
biocompatibility, biodegradability, low immunogenicity, and the capacity to deliver both 
hydrophobic and hydrophilic drugs.
68
 Hydrophobic drugs can be loaded in the lipid 
bilayers to increase the water solubility, while hydrophilic drugs can be loaded in the 
aqueous core to increase the blood circulation and reduce the drug’s side effects.69 
PEGylation of liposomes can further prevent the recognition by the reticuloendothelial 
system (RES) and increase the blood circulation, for example, Doxil
®
.
51, 68
 Liposomes can 
also be formulated with targeting moieties on the surface of the nanocarriers for active 
targeting and drug delivery.
70
 Controlling the drug release at certain site/tissue in vivo can 
achieve more precise drug delivery. Triggered drug release from liposomes by pH, 
temperature, light, and enzymes has been investigated.
71
 Liposomes have further been 
investigated as theranostic nanovectors by combining chemotherapeutic agents with 
diagnostic tracers for magnetic resonance imaging (MRI) and single-photon emission 
computed tomography/computed tomography (SPECT/CT) imaging.
72
 
Polymeric nanosystems are another large family of nanomaterials that have been 
investigated intensively in the past decades, such as dendrimers, micelles, and 
polymersomes. Different polymer building blocks such as homopolymers, copolymers and 
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triblock polymers at different chain lengths make the polymeric nanostructures very 
flexible and the properties can be tailored to meet the medical requirements. Due to the 
tunable chemical structures, the polymeric nanosystems can be easily surface modified 
and reach high drug loadings, which are very important parameters to translate them into 
clinical trials.
73
 The polymer-drug conjugates also increase the flexibility of the drug 
administration routes. For example, poly(L-glutamic acid)-paclitaxel (CT-2103, Xyotax
®
), 
developed by CTI BioPharma, is a formulation of polymer-drug conjugate that increases 
the solubility of the hydrophobic drug paclitaxel.
74
 This formulation has also increased the 
anticancer drug efficacy and reduced its side effects, as well as increased the patient 
compliance compared to standard taxanes in clinical trials.
75
 Doxorubicin and 
methotrexate as well as some other cancer drugs have been conjugated to different 
polymers to increase the therapeutic index.
76-77
 It is worth to mention here that the 
polymer-drug conjugates are prodrug-like formulations and their efficacy depends on the 
chemical structure and pharmaceutical active site of the drug. The release of the drug from 
the conjugation is critical for some drugs.
78
 Amphiphilic polymeric micelle formulations 
have a hydrophobic core, where hydrophobic drugs can be complexed. The pH, 
temperature, ionic strength and amphiphilic surfactants can affect the micelle formation, 
which in turn can be utilized for triggered drug release.
79
 Nanogel is another polymeric 
structure, which is a nanosized polymeric structure and crosslinked to increase the stability 
of the nanostructure and to obtain a sustained drug release.
80
 Depending on the crosslinker 
or the composite of the nanogel, thermal,
81
 pH,
82
 or photo-triggered
83
 drug release profiles 
can be obtained. Polymersomes, also called polymeric vesicles, are another type of self-
assembled nanostructures of amphiphilic copolymers, which have similar hydrophobic 
bilayer and hydrophilic core structures like liposomes.
84
 Polymersomes provide higher 
drug loading degrees and are more stable as compared to liposomes.
85
 Other structural 
carriers include, for example, dendrimers, which are repetitively branched molecules, with 
sizes in a range between 1 and 15 nm and near monodispersibility in a 3D structure.
86
 The 
“hole” between dendrimer units can be used for physical drug loading. Another feature of 
dendrimers is the abundant terminal groups, which can be used to conjugate drug 
molecules for sustained drug release.
77, 87
 These terminal groups can also be labeled with 
targeting moieties,
88-89
 radiotracers,
90
 or fluorescence dyes,
91
 for biomedical imaging. 
Polyamidoamine (PAMAM) dendrimer is one of the most studied dendrimers for 
anticancer drug delivery. Anticancer methotrexate (MTX) conjugated to PAMAM 
increased the cellular uptake and the binding affinity of MTX to the folate binding 
protein.
92
 
Protein molecules as drug delivery carriers have presented decent outcomes as 
nanoplatforms for drug delivery due to their biocompatibility and biodegradability.
93
 
Abraxane is the formulation of paclitaxel loaded into albumin NPs, which has been 
approved by the FDA in 2005 for the treatment of breast cancer.
94
 Protein NPs consist of 
natural protein subunits or combination of natural protein with further chemical 
modification. Albumin,
95
 gelatin,
96
 elastin,
97
 gliadin and legumin,
98
 have been studied to 
form protein-based NPs and further applied for drug delivery. 
DNA-based nanotechnology, especially DNA origami, provides another platform 
which can be used for drug and gene delivery for cancer therapy and diagnosis.
99-101
 DNA 
origami is the type of nanomaterials formed by self-assembling of DNA sequence with 
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precisely defined shapes and uniform sizes.
102-104
 Aptamer-based DNA self-assembling 
nanocomposite has been built for targeted cancer therapy.
17
 Both doxorubicin and 
therapeutic antisense oligonucleotides were co-loaded to the DNA nanostructure to 
decrease the drug resistance in vitro. A DNA microsponge containing extremely high ratio 
of repeating oligonucleotide copies was stabilized by the layer-by-layer assembly 
technique.
105
 The formulation significantly improved the nucleic acid stability in vitro 
against the DNase and during the in vivo biodistribution. A hybrid nanocomposite 
containing gold NP functionalized with double-stranded DNA and temperature-responsive 
polymer has been formed as well.
101
 Chemotherapeutic drug doxorubicin was loaded in 
the nanocomposite and a temperature controlled release profile was achieved.
101
 
Inorganic NPs, such gold NPs (AuNPs), single-wall/multiwall carbon nanotubes 
(SWCNT/MWCNT), mesoporous silica NPs, quantum dots (QDs), magnetic NPs as well 
as porous silicon (PSi) NPs are another family of investigated nanovectors for biomedical 
diagnostics and drug delivery.
50, 106-111
 In particular, most of the inorganic NPs present 
photosensitivity and can be used for photothermal therapy combined with 
chemotherapy.
106
 
AuNPs have gained great attention for biomedical applications due to the controllable 
size and superior optical properties in the near-infrared at 700 to 900 nm.
107
 AuNPs can be 
surface stabilized/modified through gold-thiolate bonds (Au-S) by disulfide (S-S) or thiol 
(-SH) bonds reacting with fresh gold surface.
112
 AuNPs have been surface functionalized 
by targeting ligands/drugs for photothermal/radiation therapy and drug delivery.
113-115
 
External light triggering of liposome/AuNPs complexed nanocomposites or polymer-
modified AuNPs by glutathione can be applied for triggered drug release and 
phototherapy.
114, 116
 
SWCNTs (0.4–2.0 nm in diameter and 20–1000 nm in length) are more suitable for 
imaging after surface functionalization.
108
 In addition, SWCNTs can also be chemically 
conjugated with drug molecules to achieve sustained drug release.
110, 117
 MWCNTs with 
sizes of 1.4–100 nm in diameter, and not less than 1 μm in length, can be used for large 
biomolecules delivery, such as plasmids.
109
 
Mesoporous silica NPs have a size range from 50 to 300 nm and pore size between 2 
and 6 nm, which can be used for both drug loading, and internal and external 
functionalization.
118-119
 ‘Cornell Dots’, which are made of silica NPs, have been approved 
for clinical phase I trials by the FDA in 2011.
120
 Mesoporous silica NPs can be 
synthesized and surface modified by co-condensation, grafting, and imprint coating 
methods.
121-122
 The surface chemistry can determine the cellular uptake mechanism of the 
mesoporous silica NPs.
123-125
 Recently, a luminescent mesoporous silica/Europium-based 
nanocomposite was prepared, which incorporated drug delivery and an ideal time-gated 
luminescence imaging without labeling.
126
 
Magnetic nanoparticles, such as SPIONs, have been used in clinic for hepatic imaging 
111
. SPIONs were synthesized by electrodeposition with controllable size range from 
nanometers to micrometers.
127-128
 SPIONs with high magnetic flux density have been 
prepared with optimal drug targeting, magnetic to heat, non-toxicity, biocompatibility, 
injectability, and surface tunability properties.
129
 NPs with sizes of 5 to 100 nm have been 
attractive for biomedical applications and widely studied in the pre-clinical stages.
130-131
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PSi NPs are another group of NPs with high potential for biomedical applications. The 
properties of these NPs will be discussed in more detail in section 2.2. 
The physical parameters and chemical composition of the NPs can dramatically 
determine the drug delivery efficacy. The surface modification is an important approach to 
improve the bio-properties of the NPs, which can affect the NPs’ interactions with the 
biological systems, and thus, modulate the biofate of the NPs in vivo, as well as the 
success of the drug delivery. The various tunable structures for surface modification are 
the advantages of these nanoplatforms in drug delivery applications. 
2.2 Porous silicon (PSi) NPs 
2.2.1 Preparation and surface chemistry 
Porous silicon (PSi) based materials are in the form of crystalline Si with nanosized pores 
in the bulk structure. The PSi structure was first fabricated accidentally by Arthur Uhlir Jr. 
and Ingeborg Uhlir at the Bell Labs in 1956.
132
 However, it was not until later in 1980s, 
that PSi started to draw attention by others due to the discovery by Leigh Canham of the 
photoluminescence property of the quantum sized highly porous crystalline Si.
133
 
Following this discovery, Canham also demonstrated that PSi can be used for biomedical 
applications by testing the cell hydroxyapatite growth on microporous Si-film.
134
  
The most common method to produce PSi nanomaterials is anodization.
6
 Briefly, Si 
wafers are immersed in an electrochemical cell containing a hydrofluoric acid 
(HF)/ethanol solution to create a porous structure. The Si wafer is placed as the anode and 
the cathode is conventionally made of platinum. Specific electric current is applied to etch 
the Si wafers. The surface area, porosity and pore size distribution (2–50 nm) depend on 
the fabrication parameters, such as current density, anodization time, temperature and HF 
concentration, as well as the Si substrate type.
6, 135
 
Freshly prepared PSi contains crystalline Si with Si hydrides (SiSixHy; x + y = 4) 
terminals, which is highly reactive by hydrolysis and oxidation (Eqs. 1–3).136 In addition, 
the Si hydride end can react slowly with ambient air and affect the porous structure and its 
optoelectronic properties.
137
 The surface stabilization freshly after preparation of the PSi 
films has been widely applied to prevent native oxidation. 
SiH4 + 2H2O → SiO2 + 4H2    (1) 
Si + O2 → SiO2     (2) 
SiO2 + 2H2O → Si(OH)4     (3) 
Thermal oxidation is one of the methods used to stabilize the fresh Si surface by 
inducing the Si hydride to OySiOH at 300–400 C.
138
 With increasing temperature, the Si 
backbone becomes oxidized by incorporating one oxygen atom within the backbone of 
Si.
139
 At 600 C and above, all the Si-Hx residues on the surface are oxidized to OySiOH 
and Si-O-Si species.
140
 This thermal oxidation creates a hydrophilic PSi surface. Aqueous 
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oxidation is another approach to form OySiOH and Si-OH species on the fresh surface of 
PSi materials.
141
 
Thermal carbonization and thermal hydrocarbonization are two alternative surface 
stabilization methods developed by Salonen in 2002 and 2004.
142-144
 These methods 
consist of treating the freshly prepared Si surfaces with acetylene at elevated temperatures. 
Thermal hydrocarbonization is performed by flushing the Si surface with acetylene at 650 
C to create a Si-C and C-H surface. Thermal carbonization obtained by heating the PSi 
materials above 700 C after the absorbance of acetylene leads to the formation of Si-C 
bonds on the surface of PSi. Thermal carbonization produces a more hydrophilic surface, 
which is more stable than after thermal hydrocarbonization. Chemically reactive groups, 
such as carboxylic acids (-COOH) and amines (-NH2), can be introduced to the above 
stabilized PSi materials by continuing the liquid phase hydrosilylation with undecylenic 
acid or (3-aminopropyl)triethoxysilane (APTES).
8, 145
 
Hydrosilylation is another approach for the surface stabilization of PSi, including Si-H 
reacting with an unsaturated compound bearing C=C, C≡C and C=O, forming Si-C-C, Si-
C=C and Si-C-O bonds, respectively, originated after the catalysis induced by heat, light, 
metal and Lewis acid reactions.
146-149
 Thermal hydrosilylation is obtained by immersing 
the hydride terminated PSi into diluted solutions of alkenes, alkynes, or aldehydes and 
refluxing for certain times.
149
 Further functional moieties can be introduced by using the 
link molecules containing chemical reactive groups at the opposite end. Light 
hydrosilylation involves illuminating the PSi in a neat alkene or alkyne with tungsten or 
mercury lamp at room temperature.
150-151
 Light hydrosilylation can prevent oxidation and 
form photopatterns by controlling the light illumination.
151
 For example, 1,6-heptadiyne 
and 1,8-nonadiyne have been introduced onto the PSi surface by thermal or light 
hydrosilylation to obtain alkyne-terminated surfaces and further attached to PEG, methyl, 
alcohol, amine, and bromine via click chemistry.
152-154
 
Metal ions (rhodium and platinum) can catalyze the hydrosilylation, enabling to 
achieve some functionalization onto the PSi surface, which are not possible by other 
functionalization routes.
6
 However, in the case of biomedical applications, the risk of 
metal ions contamination is not optimal. Lewis acids (EtAlCl2) catalyzing the 
hydrosilylation can introduce alkenes and alkynes to the surface of PSi in a solution at 
room temperature, although this is a rather slow process.
155
 
Anodization is one of the top-down approaches to prepare PSi nanomaterials. It is 
carried out by etching the Si wafer in HF solution to generate porosity, which causes high 
Si mass loss. Recently, bottom-up approaches to prepare PSi have been under 
investigation. One of the methods is magnesiothermic reduction of silica to produce 
PSi.
156
 Sodiothermic reduction of zeolite NaY can achieve higher surface area than the 
magnesiothermic method. Both of the methods need pre-formed porous materials as the 
precursor.
157
 Porous Si/C composite materials use a chemical vapour deposition method. It 
is an effective bottom-up approach, but the produced Si unit is not porous.
158
 Wet 
chemical synthesis is used to produce mesoporous crystalline Si materials by reduction of 
Si halogenide precursor (SiCl4) and the production of salts precipitated for self-templating 
in order to synthesize PSi materials without chemical corrosion of Si.
159
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2.2.2 Biomedical applications 
2.2.2.1 Biocompatability of PSi 
The biocompatibility is the first characteristic of the biomaterials that needs to be assessed 
before applying it in healthcare. The biocompatibility of PSi has been investigated 
extensively both in vitro and in vivo.
160-165
 Thermally-oxidized, aminosilanised PSi 
membranes were planted under the rat conjunctiva and underwent slow dissolution to 
silicic acid by colorimetric assay, but remained visible at the operating microscope for 
more than 8 weeks.
166
 At the end-stage, histological assessment displayed that there was a 
thin fibrous capsule surrounding the implant, but little evidence of any local accumulation 
of acute inflammatory cells or vascularization were observed. In another study, three types 
of PSi particles (freshly etched particles, thermally hydrosilylated, and thermally oxidized 
particles) were injected into the rabbit vitreous to evaluate the stability and toxicity of each 
type of particles by ophthalmoscopy, biomicroscopy, tonometry, electroretinography and 
histology.
167
 The results showed that no toxicity was observed with all three types of the 
particles during the more than 4 months study period. The surface alkylation led to 
significant increase in the intravitreal stability and slower degradation (t1/2 1 week vs. 5 
weeks vs. 16 weeks). Further elimination of the Si element from the vitreal was 
investigated for fresh PSi and oxidized PSi by quantifying the Si from the samples of 
aqueous, vitreous and retina compartments by inductively coupled plasma-optical 
emission spectroscopy.
168
 
Thermally hydrocarbonized PSi (THCPSi) and thermally oxidized PSi (TOPSi) 
particles have been reported to induce non-significant toxicity, oxidative stress, or 
inflammatory response in vitro to colon cancer cells Caco-2 and mouse leukemic 
monocyte macrophages RAW 264.7. However, in vivo the 
18
F-labeled THCPSi NPs 
passed intact through the gastrointestinal track after oral administration and there was no 
absorption observed from the subcutaneous deposit.
160
 The surface chemistry of PSi NPs 
also affects the biocompatibility of PSi NPs. Negatively charged hydrophilic (TCPSi and 
TOPSi) and hydrophobic (THCPSi) NPs induced less ATP depletion and genotoxicity 
than positively charged PSi NPs on immune cells and human red blood cells (RBCs).
161
 
Figure 3 shows the effect of the PSi NPs with different surface chemistries on the cell 
morphology in RBCs. In another study, the myocardial infarction injection of THCPSi 
microparticles (7 and 19 μm) induced higher activation of inflammatory cytokine and 
fibrosis promoting genes compared to TOPSi microparticles (7 and 19 μm) and NPs (110 
nm), but none of the particles affected the cardiac function or the hematological 
parameters.
162
 
In another recent report, the acute immunotoxicity and subacute toxicity of PSi-based 
multistage siRNA delivery composite was addressed in vitro and in vivo.163 The siRNA 
loaded composites did not increase the level of TNF-α or IL-6 in RAW 264.7 cells, nor 
triggering secretion of proinflammatory cytokines and chemokines, such as IL-1β, 
interferon-γ, and MCP-1, was observed in vivo after the intravenous administration. The 
subacute toxicity was studied by administration of this composite once a week for four 
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weeks and the mice were sacrificed 24 h after the final treatment. The results showed that 
the repeated treatments did not cause damages to major organs in the wild-type mice. 
 
Figure 3. Effect of different PSi NPs on the morphology of RBCs. Few TOPSi and THCPSi NPs 
were associated on the surface of erythrocytes with low morphological alterations, 
while higher amounts of (3-aminopropyl)triethoxysilane functionalized TCPSi (APS-
TCPSi) and undecylenic acid functionalized (UnTHCPSi) NPs were associated with 
the erythrocytes and induced cell membrane wrapping and shrinking around the PSi 
NPs. Copyright © (2013) Elsevier B.V. Reprinted with permission from ref. 
161
. 
Besides the biocompatibility, the degradation of the NPs is also an important 
parameter for biomedical applications. The product obtained from the degradation of PSi 
is orthosilicic acid [Si(OH)4], which is a common trace element in humans and is naturally 
found in numerous tissues.
169-170
 But the degradation profiles of PSi depend, for example, 
on the fabrication method, surface properties, porous size, and porous volume.
167-168, 171-172
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Park et al. reported the in vivo degradation of luminescent PSi NPs administered 
subcutaneously, intramuscularly, and intravenously to mice, monitored by near-infrared 
photoluminescence.
173
 The intravenously administered PSi NPs were eliminated in 4 
weeks and the dextran-coating decreased the degradation rate of the NPs. There was no 
significant histopathological toxicity observed in the liver, spleen, and kidney. The studies 
indicated that the aqueous vitreous humor was a significant pathway for Si elimination 
from the eye following the intravitreal injection of PSi particles. 
2.2.2.2 PSi for drug delivery applications 
The nanoporous structure and the high surface area-to-volume ratio of PSi render it a 
potential carrier for drug delivery purposes. The most common method of loading 
payloads to PSi is physical adsorption.
174
 In addition, chemical conjugation of drugs to the 
surface of PSi is an alternative to obtain sustained release of the payloads from PSi 
175-176
. 
Small conventional drugs, peptides, proteins as well as nucleotides have been loaded into 
PSi materials for drug delivery applications.
163, 174, 176-182
 
Surface stabilized PSi has been more commonly used for drug delivery applications. 
Freshly etched PSi NPs with Si-Hx (x = 1, 2 or 3) can react with redox active drugs and 
destroy the bioactivity of the drugs.
175
 To avoid this, the anthracycline drug daunorubicin 
was conjugated to undecylenic acid terminated PSi particles for long-term drug 
delivery.
175
 The three different methods used to stabilize the PSi particles were 
hydrosilylation in the presence of neat undecylenic acid, hydrosilylated PSi by air 
oxidation at 150 C, and high temperature oxidation at 800 C in air for 1 h. None or 
minor amounts of daunorubicin were detected in the release buffer from the first and 
second type of PSi particles due to the redox reaction of the residue Si-H species with 
daunorubicin. For daunorubicin conjugated PSi particles at high temperature oxidization, 
the major compound from the release media was daunorubicin. The results indicated that 
all the S-H or elemental Si species on the PSi particles used for drug delivery should be 
removed to avoid the reaction with redox-active drugs.
175
 
In 2005, Salonen et al. studied five model drugs belonging to different 
biopharmaceutics classification system (BCS) categories (antipyrine, BCS class I; 
ibuprofen and griseofulvin, BCS class II; ranitidine, BCS class III; and furosemide, BCS 
class IV) loaded into TCPSi and TOPSi microparticles for oral drug delivery 
applications.
174
 The results showed that the surface chemistry of PSi affected the drug 
affinity to the PSi particles, and thus, the drug loading degree. The nature of the drug and 
the loading solutions played critical roles in the drug loading efficiencies. PSi particles 
enhanced the dissolution rate of the poorly-water soluble drugs due to the disordered 
(amorphous) drug molecules adsorbed onto the surface of the inner wall of the nanosized 
PSi structure. 
In another study, the physical state of the small drug molecule, ibuprofen, loaded into 
THCPSi particles with a loading concentration of 350 mg/mL of ibuprofen in ethanol was 
studied using three experimental methods (nitrogen sorption, thermogravimetry, and 
differential scanning calorimetry).
183
 Three thermodynamically different states of 
ibuprofen were found: (1) a crystalline state outside the pores; (2) a crystalline state inside 
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the pores; and (3) a disordered state adjacent to the inner wall of the pores. Other studies 
have shown that TOPSi and THCPSi particles increased the permeability of poorly-water 
soluble drugs, griseofulvin and indomethacin, across the Caco-2 monolayer, which is an in 
vitro model used to mimic the intestinal epithelial cell barrier.
180, 184
 Tablet formulations 
made from 25 weight-% of indomethacin (IMC)-loaded TOPSi microparticles were shown 
to increase the dissolution rate and drug permeability across Caco-2 monolayers of 
IMC.
185
 In vivo orally administered IMC-loaded in TOPSi particles achieved enhanced 
oral delivery performance in comparison with crystalline IMC and Indocid

, showing a 4-
time reduction on Tmax, a 200% increase on Cmax, as well as a significant increase in the 
IMC bioavailability.
186
 Figure 4 shows the plasma concentration profiles of IMC-loaded 
TOPSi microparticles, the commercially available formulation Indocid

, and free IMC on 
a fasted rat model after oral administration. 
 
Figure 4. Plasma concentration profiles of IMC-loaded TOPSi (◊), Indocid

 (□) and free IMC (Δ) 
in a fasted rat model after oral administration. Copyright © (2010) the American 
Chemical Society. Reprinted with permission from ref. 
186
. 
Peptides have also been loaded into PSi for biomedical applications. For example, D-
lys-GHRP6 (ghrelin antagonist) was used as a model peptide to study the loading, release 
and biological activity both in vitro and in vivo.
177
 The pharmacological activity of the 
peptide was remained after the adsorption loading procedure. In vivo the peptide loaded in 
THCPSi microparticles presented a prolonged release effect compared with the peptide in 
solution after subcutaneous administration. Kovalainen et al. studied the effect of PSi 
particles with various surface chemistries on endogenous peptide YY3-36 (PYY3-36) 
delivery both in vitro and in vivo.
178, 187
 In vitro and in vivo sustained release of PYY3-36 
was in the same order and the release rate followed the order: TOPSi > THCPSi > 
UnTHCPSi. In vitro, the highest release from TOPSi was 27% after 14 days, which was 
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still not the completed release of PYY3-36. However, the in vivo sustained release of 
PYY3-36 for all the PSi particles lasted for more than 4 days. The bioavailability of 
PYY3-36 reached 98% for the loaded TOPSi particles and only 38% for the PYY3-36 
solution when administered subcutaneously, with a half-life increase of 21 h vs. 25 min. In 
another study, co-loading of PYY3-36 and IMC into PSi enhanced the dissolution rate of 
both drugs.
181
 On the other hand, glucagon-like peptide 1 (GLP-1) loaded into TOPSi, 
TCPSi, and amine-modified TOPSi and TCPSi particles did not achieve sustained release 
in vitro or in vivo after subcutaneous injection, however, the amine-terminated particles 
increased the adsorption of GLP-1 onto PSi microparticles.
179
 Furthermore, chitosan 
coating increased the permeation of GLP-1 loaded in PSi NPs across an intestinal in vitro 
model.
188
 The surface chemistry of the particles affects the peptide loading and release, 
and each peptide interaction with the PSi particles also depends on the properties of the 
peptides. 
Protein drug delivery has been an increasing area for pharmaceutical research. The 
tailorable porosity of PSi can be used for encapsulation and delivery of proteins. For 
example, lysozyme, papain and human serum albumin (HSA) were loaded into the 
unoxidized and thermally oxidized PSi particles.
189
 For all the three proteins, the 
unoxidized PSi particles presented higher loading degrees compared to the oxidized PSi 
particles, but a change in the proteins’ structure occurred. This might be due to the highly 
reactive Si-H species on the surface of the PSi particles. Thermally oxidized PSi heated at 
800 C retained the protein structures of lysozyme and papain, but not HSA. Due to the 
hydrophobicity/hydrophilicity interactions, electrostatic attraction and the high surface 
area inside the pores of the particles, the protein interacts with the PSi particle and is 
oriented in a different way from the protein in physiological conditions. The 
pharmacological activity of the loaded protein should be studied individually case by case. 
Insulin has also been loaded to PSi particles and nearly 10-fold higher permeability across 
intestinal Caco-2 cell monolayer was achieved compared to the insulin solution alone.
190
 
In another report, chitosan-conjugated UnTHCPSi microparticles also enhanced 
extensively the permeability of insulin across the Caco-2/HT-29 cell monolayers.
191
 
Gene therapy has been one of the novel model approaches to treat genetic defects and 
cancer, particularly the traditionally considered “non-druggable” genetic diseases.192 For 
example, siRNA has been involved to knock-down the drug resistant gene when co-
delivered with chemotherapeutic agents for multidrug resistant cancer therapy 
193
. PSi-
based nanomaterials have also been studied for gene delivery. However, different from 
conventional small drug molecules or peptides/proteins, negatively charged plasmid DNA 
and siRNA have not been directly loaded to the stabilized PSi nanomaterials for gene 
delivery. Multistage stage PSi-based vectors encapsulating siRNA for cancer therapy have 
been reported both in vitro and in vivo.
194-195
 The developed multistage vectors, siRNA 
targeted proteins and the in vitro and in vivo effects are listed in Table 2. The 
representative in vivo success of siRNA delivery and biocompatibility at the therapeutic 
dose of PSi-based multistage complex systems give the dawn of the PSi materials for 
clinical applications. 
32
P BioSilicon, which is made of PSi materials loaded with 
32
P 
isotope, is currently used in brachytherapy for pancreatic cancer treatment in clinical trials 
phase III.
196-197
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Table 2. Summary of the PSi-based multistage siRNA delivery systems. 
Multistage PSi-
siRNA system 
siRNA 
targeting 
Results Ref 
APTES stabilized 
PSi microparticles 
loaded with neutral 
siRNA-DOPC
1
 
nanoliposome 
 
EphA2 
oncoprotein 
Sustained EphA2 gene silencing for at least 3 
weeks in ovarian cancer model following a single 
intravenous administration and reduced tumor 
burden, angiogenesis and cell proliferation 
194
 
EphA2 
oncoprotein  
Combination treatment with paclitaxel 
completely inhibited SKOV3ip2 tumor. Combination 
with docetaxel inhibited tumor growth of HeyA8-
MDR tumor 
195
 
APTES stabilized 
PSi microparticles 
modified with arginine-
PEI
2
 inside the 
nanopores 
STAT3 
siRNA or 
GRP78 
siRNA 
91% (STAT3)
3
 or 83% (GRP78)
4
 reduction of 
gene expression in MDA-MB-231 cells. In murine 
model of MDA-MB-231 breast cancer reduced 
STAT3 expression in cancer cells, and significant 
reduced cancer stem cells in the residual tumor 
tissue, with no triggered acute immune response 
163
 
APTES stabilized 
PSi microparticles 
loaded with siRNA-
DOPC nanoliposomes 
ATM 
siRNA 
Biweeky treatment, suppressed ATM
5
 
expression in tumor tissues, inhibited growth of 
MDA-MB-231 orthotopic tumor. No acute immune 
response was observed 
198
 
APTES stabilized 
PSi microparticles 
modified by ESTA
6
, 
loaded with 
siRNA/PEG-PEI 
siRNA 
targeting to 
the human 
STAT3 
gene 
 
Knock-down of STAT3 expression in 48.7% of 
cancer cells inside the bone marrow. Weekly 
systemic administration significantly extended 
survival of mice with MDA-MB-231 bone metastasis 
199
 
TEIC
7
 stabilized 
PSi microparticles 
loaded with siRNA/PEI 
complex 
siRNA 
against 
ATM 
siRNA/PEI complexes induced dramatic gene 
silencing in vitro and enhanced biocompatibility 
200
 
1DOPC: 1,2-dioleoyl-sn-glycero-3-phosphocholine; 2PEI: polyethyleneimine; 3STAT3: essential gene for breast cancer 
stem cells; 4GRP78: gene encodes a 78-kDa glucose-regulated protein; 5ATM: ataxia-telangiectasia mutated; 6ESTA: E-
selectin thioaptamer. 7TEIC: 3-(triethoxysilyl)propyl isocyanate. 
2.2.2.3 PSi for imaging applications 
In addition to the drug loading capacity, PSi nanomaterials have been employed as a 
potential imaging tool for biomedical application, such as cancer imaging.
201
 The imaging 
properties of the materials give the possibility to assess and monitor the biofate of the 
developed drug nanocarriers in vivo. 
Fluorescent-labeled PSi NPs have been used for in vivo cancer imaging.
202
 After 
targeting peptides functionalization, accumulation of the fluorescent PSi NPs was 
followed in the tumor tissue. In another study, both Quantum-dots and SWCNTs have 
been loaded into PSi to form multistage fluorescent vectors.
203
 This study also showed that 
the surface chemical properties of both the nanocomposites affected the loading efficiency 
and stability of the assembled multistage carrier systems.  
Sarparanta et al. developed a direct one-step 
18
F-radiolabeling reaction suitable for 
three types of PSi particles (THCPSi, TCPSi, and TOPSi).
204
 All the three radiolabeled 
20 
 
particles presented excellent radiolabeling stability in simulated gastric and intestinal 
fluids and in plasma. Furthermore, the 
18
F-labeled THCPSi NPs was used to monitor the 
in vivo fate of THCPSi NPs after oral administration (Figure 5),
160
 and intravenous 
administration.
205
 
 
Figure 5. Macroautoradiographs and respective photographs of the gastrointestinal tracts of rats 
at 2, 4, and 6 h after oral administration of 
18
F-labeled THCPSi NPs (a) and free 
18
F-
NaF (b). Abbreviations denote: Duo, duodenum; Je, jejunum; Ile, ileum; Ce, cecum; 
Asc, ascendens; Tra, transversum; and Des, descendens. Copyright © (2010) the 
American Chemical Society. Reprinted with permission from ref. 
160
. 
Luminescent colloidal Si suspension was reported in 1992.
206
 Following the high 
quantum yield, Si nanocrystals were fabricated.
207-208
 The luminescence of PSi NPs 
displayed radiation lifetimes in the order of 100 ns to several microseconds, which can be 
used for late time-gating (capturing the signal at a delayed time after excitation) to reduce 
the tissue autofluorescence.
209
 In 2009, Park et al. developed biodegradable luminescent 
PSi NPs used for in vivo imaging.
173
 In vitro, the PSi NPs degraded into silicic acid and 
lost the luminescence very fast (80% loss of luminescence in 1 h) after incubation in 
21 
 
buffer solution (pH 7.4, 37 C). The in vivo biodistribution and degradation of this 
luminescent PSi NPs can be monitored non-invasively in live animals by microscopy. The 
in vivo administered luminescent PSi NPs did not present any toxicity. Gu et al. reported 
luminescent PSi NPs displaying sufficiently long lifetimes (5-13 μs) to permit late time-
gate imaging.
201
 This PSi-based luminescent probe presented the improvement of signal to 
background contrast ratio by more than 50-fold and 20-fold in vitro and in vivo, 
respectively. 
PSi NPs have been utilized as cargos to encapsulate the magnetic resonance imaging 
(MRI) contrast which were further investigated for MRI.
210-211
 In 2010, Ananta and Godin 
reported three gadolium-based contrast agents  magnevist, gadofullerenes and 
gadonanotubes were loaded inside the porous structure of PSi particles.
210
 By loading to 
the PSi particles, the relaxivity values were about 4- to 50-fold higher than those of the 
gadolinium-based agents in clinical use. The mechanism of enhancing the relaxivity was 
due to the geometrical confinement of the agents which further affect the paramagnetic 
movement of the Gd
3+
 ions. Magnetic NPs (Fe3O4) has been trapped into the PSi NPs.
211
 
The MRI contrast was significantly enhanced by controlling over the clustering of iron 
oxide NPs in the pores of the PSi NPs. 
2.3 Biological barriers and surface modification of drug carriers 
2.3.1 Biological barriers and targeting drug delivery 
2.3.1.1 Intestinal barriers 
After a drug is administered in the body, there are several biological barriers before the 
drug reaches the targeting site and generates the pharmacological effect.
212
 The most 
common drug delivery route is oral drug administration. Some cancer drugs can be applied 
for oral administration in clinics, such as methotrexate and sorafenib.
213-214
 For oral drug 
delivery, the first obstacle is the acidic conditions in the stomach. Coating or 
encapsulation with acidic insoluble polymers has been one of the approaches to help the 
drugs to overcome the acidic conditions and safely pass from the stomach to the intestine. 
The major adsorption of the orally administered drug occurs at the small intestine due to 
the large surface area with the presenting of villi and microvilli.
215
 For many small drugs, 
as well as peptides and proteins with low permeability across the intestinal wall, 
modification of the drug formulation with intestinal mucus adhesive materials, for 
example chitosan, could increase the drug adsorption.
216
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2.3.1.2 Plasma Protein barrier 
The plasma barrier is the first biological barrier for the intravenously delivered NPs. Due 
to the physicochemical properties, NPs can be surrounded by protein corona in less than 
one second after intravenous administration.
22
 In plasma, the most abundant protein is 
serum albumin, followed by the more hydrophobic protein, fibrinogen. The 
immunoglobulins, complement proteins, and fibrinogen proteins are the major proteins 
related to the immune system, which can stimulate the phagocytosis by the mononuclear 
phagocyte system (MPS).217 Complement C3 associated to the NPs triggered the 
recognition and elimination by macrophages when the complement C3 protein is 
converted to the C3a/b form.
24
 For many low water-solubility anticancer drugs, NP-based 
drug delivery systems are used to increase the aqueous solubility of drugs, and this has 
been a hot field for anticancer drug delivery.
65
 Nanoparticulated chemotherapeutic drug 
formulations for intravenous administration can achieve 100% bioavailability, with 
reduced incidence of serious side effects in the intestine.
218
 However, the protein corona 
can dramatically determine the biofate of the NPs. When NPs are recognized by the 
immune system macrophages, the NPs will be mainly transported to the liver and spleen 
and fail to deliver the drug to the desired site.
219
 High molecular weight polyethylene 
glycol (PEG) and dextran have been investigated as hydrophilic polymers to sheath the 
surface of the NPs and aid to prevent the plasma protein association.
24, 220
 
2.3.1.3 Cancer tissue/cell uptake and endosomal escape 
For chemotherapy, only the anticancer drugs reaching the cancer tissue will function and 
inhibit the cancer growth.
221
 Directing the anticancer drugs or drug loaded carriers to the 
cancer tissue is one of the major steps for chemotherapy. Due to the rapid dividing of 
cancer cells and formation of neovasculature, the blood vessels in the cancer tissue are 
leakier than the established blood vessels in healthy tissues.
222
 NPs circulating in the 
bloodstream can penetrate the leaky blood vessels into the tumor tissue,
223-224
 which is a 
passive targeting drug delivery approach. In addition, numerous molecular biomarkers at 
the surface of the neovascular endothelial cells and cancer cells have been identified, as 
well as the targeting ligands which have specific high affinity to the biomarkers.
225
 
Surface modification of the NPs with the specific ligands can increase the interaction of 
the NPs with the cancer tissue, and thus, increase the drug delivery efficiency.
10, 226
 
Some cancer drugs work by intercalating DNA synthesis, such as doxorubicin, 
paclitaxel, cisplatin,
227-229
 or inhibiting the enzyme involved in DNA synthesis during cell 
proliferation, such as methotrexate.
230
 These kinds of anticancer drugs have to be 
delivered into the cytoplasm or nuclei. The negatively charged cell membrane is another 
barrier for the delivery of anticancer drugs into the cytosol. Enhancing the cellular uptake 
of the drugs or NPs is one of the approaches for chemotherapeutical drug delivery 
development. It has been reported that cationic charged nanocarriers can increase the 
interaction with the cell membrane and induce endocytic cellular uptake.
231-232
 Thus, for 
low cellular uptake of drug molecules or to overcome multidrug resistance, researchers 
have investigated the use of cationic nanovector-based drug delivery approaches.
233
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Cell membrane receptor-mediated uptake of NPs is another approach to increase the 
cellular uptake of the nanocarriers.
92, 234
 Integrins, vascular endothelial growth factor 
(VEGF) or transforming growth factor α (TGF-α) are the common biomarkers of the 
neovascular endothelial cells.
235
 Targeting ligands, such as peptide arginine-glycine-
aspartic acid (RGD), VEGF receptors, TGF receptors, can be incorporated onto the 
surface of nanocarriers and increase the cellular uptake of the nanocarriers for anticancer 
drug delivery.
236-238
 
The endocytic cellular uptake pathway is the major mechanism for the nanocarriers by 
the cells.
239
 Following the endocytosis, endosome escape to the cytoplasmic compartment 
is an important step for certain drugs, especially the biological drugs, such as peptides, 
proteins, and genes. The mechanisms of endosome escape include: (1) pore formation in 
the endosomal membrane; (2) the proton sponge effect; (3) fusion in the endosomal 
membrane; and (4) external photochemical disruption of the endosomal membrane.
239
 
2.3.1.4 Targeting drug delivery 
The concept of actively targeted drug delivery is attractive, because it recapitulates 
some of the advantages of typical application of drugs, such as increasing the local 
concentration and lowering the systemic exposure.
11-12
 Tumor blood vessels express 
biomarkers that are not present in resting blood vessels of normal tissues, but can be 
shared by angiogenic vessels in non-malignant conditions.
11
 Among these biomarkers, a 
number of cell-specific epitopes have been explored to show specific binding to certain 
antibodies, peptides or small molecules.
12, 238, 240
 These differentially expressed biomarkers 
can be used as docking sites accumulating drug molecules and/or drug carriers at the 
tumor tissue, which is described as targeting drug delivery. 
Targeting peptides, aptamers, antibodies, as well as small molecules have been used to 
increase the specific targeting delivery of nanocarriers.
7, 13, 241-242
 The three-amino acid 
peptide RGD was identified as a ligand for integrins, such as ανβ3, ανβ5, and α5β1.243-244 
Intravenously administrated RGD-targeted nanovectors are capable to deliver a payload of 
antiangiogenic or antitumor agents to tumor sprouting tissue while sparing healthy tissues. 
RGD-modified NPs superiorly accumulated within the tumor-associated blood vessels, but 
showed little binding to other vascular beds.
241, 245
 iRGD is a disulfide-based 9-amino acid 
cyclized peptide, identified by phage display as a tumor targeting and tissue penetrating 
peptide.
244
 It can first associate with tumor cells by specific affinity to ανβ3/5 integrins on 
the tumor endothelium. On the cell membrane, iRGD is cleaved between lysine 
(K)/arginine (R) and glycine (G) by proteolysis to produce a C-terminal motif, which can 
form neuropilin-1 mediated cell internalization. The iRGD surface modified nanovector 
incorporates both tumor targeting and tissue penetrating properties to the drug delivery 
vectors.
241
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2.3.2 Pre- and post-surface modification of nanovectors 
Surface functionalization is an important approach to modulate the properties of 
nanomaterials for biomedical applications, such as to introduce fluorophores for 
fluorescent imaging,
202
 and chelators for radiolabeling,
246
 hydrophilic targeting moieties 
for targeted drug delivery,
236
 or antifouling polymers to prevent plasma protein 
association.
247
 
Biofunctionalized nanocarriers can be prepared by pre- or post-functionalization 
approaches.
248-249
 Both approaches have their advantages and disadvantages. Pre-
functionalization needs to synthesize the functionalized building blocks prior the 
formation of the NPs. With this method, the ratio of the functional moiety on the 
nanocomposite’s surface can be controlled accurately.72 On the other hand, this approach 
demands that the building blocks and reaction reagents need to be dissolved well in the 
same solution. The functionalized moiety might disturb the self-assembling formation 
process.
250
 Post-functionalization is the way that the nanostructural carrier is prepared 
before the functionalization. The post-modification ensures the functional moiety on the 
surface of the nanocarrier. However, the functionalization ratio is usually limited by the 
crowdedness on the surface of the NPs. In addition, it might be problematic to remove the 
unreacted species in some cases.
250
 Post-surface functionalization has been more 
commonly used for inorganic nanosystems modification, such as carbon nanotubes,
246
 
quantum dots,
251
 SPIONs,
252
 mesoporous silica,
16
 or the more rigid polymer-based 
nanosystems.
250
 Various chemical reaction linkages that can be used for surface 
modification of NPs are listed in Figure 6.
253
 Among these reactions, click chemistry has 
gained abundant attention during the past decade due to the efficiency and high selectivity 
to conjugate biomolecules.
254
 
2.3.3 Click chemistry reactions 
Click chemistry was reported by Sharplees in 2001 as a simple method to couple organic 
molecules in high yields under mild conditions and high selectivity in the presence of a 
diverse range of functional groups.
255
 One of the most widely used examples of this class 
of extremely efficient chemical reactions is the copper catalyzed azide-alkyne 
cycloaddition (CuAAC) reaction. Due to its high thermodynamic driving force, usually 
greater than 20 kcal/mol, the click reaction normally proceeds rapidly to completion and 
also tends to be highly selective.
19
 Both reaction active groups (azide and alkyne) are 
almost entirely inert to the functional groups, such as amines, carboxylic acids, thiols etc., 
which widely exist in many molecules. CuAAC is interesting for NPs’ surface 
biofunctionalization, because of the high specificity, efficiency and mild reaction 
conditions to preserve the bioactivity of some biomolecules.
19
 Strain promoted azide-
alkyne cycloaddition (SPAAC) click reaction, which is also called copper-free click 
reaction, becomes an alternative for the copper catalyzed click reaction.
256-257
 SPAAC 
avoids using copper ion as a catalyst, which could induce cell and further in vivo 
biological toxicity. SPAAC has become an interesting tool for surface modification of 
biomaterials and coupling functional molecules to the NPs’ surface for drug delivery 
25 
 
and/or in vivo imaging applications. Bicyclononyne (BCN) and dibenzylcyclooctyne 
(DBCO) are two of the most commonly used moieties containing the strain-promoted 
alkyne components.
257
 
 
Figure 6. Common chemical reactions used for molecular conjugation. Copyright © (2011) 
Elsevier B.V. Reprinted with permission from ref. 
253
. 
2.3.4 Surface modification of PSi materials 
During primary stabilization of the freshly prepared PSi materials, chemically reactive 
moieties can be introduced to the surface of PSi as discussed in section 2.2.1. These 
functional end-groups can be further chemically reacted with various molecules for 
different purposes. Ciampi et al. reported surface modification of acetylene-terminated PSi 
films by CuAAC.
152
 The two-step hydrosilylation/cycloaddition procedure has achieved 
growing interest in chemical functionalization where the modified surface displayed 
lowered nonspecific bovine serum albumin adsorption. In one study published in 2008, 
different functionalization of the internal and external surfaces of the PSi films was 
achieved.
258
 The fresh PSi surface was stabilized by alkyne monolayer to achieve 
hydrophobic surface which can completely prevent the access of water. The external 
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surface of the PSi was modified in aqueous solution. Next, the internal surface was pre-
wetted with ethanol, and thus, was accessed for modification. The external surface grafted 
RGD peptide increased the cell adhesion to the PSi films. Furthermore, a route to 
differently surface modifying the external and internal surfaces of PSi material was 
achieved by CuAAC.
153
 A highly parallel PSi biosensor platform was prepared by α.ω-
diyne adsorption to the photonic PSi monolayer and modified by click chemistry in the 
presence of titanium mask.
259
 Chemical conjugation of PEG onto the PSi’s surface can 
prevent albumin adsorption, whereas the smaller protein lysozyme adsorption was of very 
low extent.
154
 The anionic porphyrin-grafted to hydrosilylation stabilized PSi NPs were 
delivered inside breast cancer cells for more efficient photodynamic therapy.
176
 In this 
study, the PSi NPs were stabilized by hydrosilylation with allyl isocyanate. The antibody 
was conjugated to 1,8-nonadiyne stabilized PSi microparticles for selective binding to the 
targeted cell type over the others.
242
 In another study, three antibodies have been used to 
functionalize PSi NPs for targeted delivery of hydrophobic drug camptothecin.
260
 These 
three antibodies MLR2 (monoclonal antibody to p75NTR), mAb528 (monoclonal 
antibody to EGFR) and Rituximab (monoclonal antibody to CD20) were used to target 
neuroblastoma, glioblastoma and B lymphoma cells, respectively. E-selectin thioaptamer 
ligand, which can target to E-selectin, was conjugated to the APTES modified PSi 
particles for bone marrow targeted drug delivery.
7
 Hyaluronic acid, which can target the 
CD44 over-expressed cancer cells, were amine modified and conjugated to carboxylic acid 
terminated PSi NPs for breast cancer targeting.
261
 The developed NPs showed enhanced 
cellular interaction and internalization in breast cancer cells. 
Physical coating is another important method to improve the targeting properties of 
PSi. Hydrophobin II protein coating increased the biocompatibility and wettability of PSi 
particles, as well as the mucus adhesion of the NPs in vivo.
262-264
 In addition, the 
hydrophobin protein coating did not affect the drug loading and the drug release profiles 
of the bare PSi particles.
262
 In order to evade the immune system, cellular membranes 
purified from leukocytes were used to coat PSi particles.
265
 These hybrid particles (called 
leukolike vectors) showed enhanced circulation time and improved accumulation in the 
tumor. 
In summary, surface modification of the NPs can modulate the surface properties of 
the NPs, which can intensively affect the biofate and the function of the nanocarriers in 
vivo. By considering the functional mechanism of the biological system, drug delivery 
systems can be chemically surface modified to introduce desired bioactive properties for 
more specific cancer drug delivery applications. 
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3 Aims of the study 
The main aim of this dissertation was to employ different chemical approaches to improve 
the drug delivery efficiency, particularly by using the PSi platform for both cancer therapy 
and imaging and targeting peptides conjugated to oligonucleotide via click chemistry. The 
conjugation routes for PSi NPs and oligonucleotides were investigated, including the 
versatile SPAAC and CuAAC click conjugation methods. The developed PSi NPs were 
prepared and characterized, and the proof-of-concept demonstrated both in vitro and in 
vivo. 
The specific objectives of this study were: 
 
1. To conjugate targeting peptides to cationic PSi (amine terminated) via SPAAC for 
enhanced intracellular drug uptake of the NPs (I). 
2. To prepare multifunctional anionic PSi NPs (carboxylic acid terminated) for 
theranostic studies by SPECT/CT in vivo and fluorescence microscopy ex vivo (II). 
3. To surface functionalize alkyne terminated PSi NPs by targeting peptides and anti-
fouling polymers via CuAAC, and to study the effect of the NPs on the cellular 
uptake and human plasma protein adsorption (III). 
4. To conjugate targeting peptides to oligonucleotide via CuAAC for targeting 
angiogenic anti-inflammation (IV). 
5. To sustain the release and enhance the cellular uptake of MTX by chemical 
conjugation of MTX to PSi, as well as to co-load hydrophobic antiangiogenic drug, 
sorafenib, to the MTX-PSi NPs for combination cancer therapy (V). 
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4 Experimental 
This experimental section summarizes the experimental methods used in this dissertation. 
More detailed information on the materials and methods used in this work can be found in 
the respective original publications (I–V). The primary surface stabilized PSi NPs (I–III 
and V) were fabricated at the Laboratory of Industrial Physics, Department of Physics and 
Astronomy, University of Turku. The Radiolabeling of the PSi NPs was performed at the 
Laboratory of Radiochemistry, Department of Chemistry, University of Helsinki. 
4.1 Preparation of primary surface stabilized PSi NPs (I–III, and V) 
PSi films were fabricated prior to the NPs’ preparation. Monocrystalline p+-type Si100 
wafers with the resistivity of 0.01–0.02 Ωcm were electrochemically etched to multilayer 
Si-H terminated PSi films, as reported elsewhere.
8
 The electrolyte used was 1:1 (v/v) 
hydrofluoric acid (HF, 40%)-ethanol. Thermally hydrocarbonized PSi (THCPSi) films 
were obtained by heating at 500 C under 1:1 N2-acetylene flow for 15 min. Thermally 
carbonized PSi (TCPSi) films were obtained by heating the THCPSi films absorbed with 
acetylene at 820 C for 10 min. 
TCPSi films were immersed in HF to generate the silanol terminals. Next, the TCPSi 
films were placed in 10 v-% APTES-toluene solution to obtain aminopropylsilane-TCPSi 
(APS-TCPSi) films. The NPs were obtained by wet-milling of the APS-TCPSi films using 
a 5 v-% APTES-toluene solution as the milling liquid. The final size selection of the NPs 
was done by centrifugation. 
THCPSi films were activated to silanol terminals by immersing in HF. Carboxilyc 
acid-terminated THCPSi (UnTHCPSi) films were obtained by treating the activated 
THCPSi films in undecylenic acid at 120 C for 16 h to obtain terminated carboxylic acid 
films, adapting the thermal addition process described elsewhere.
178
 Next, the UnTHCPSi 
NPs were prepared by wet-milling in undecylenic acid and then centrifuged to obtain the 
required PSi NP size. 
Alkyne-terminated THCPSi films were fabricated in such a way that the activated 
THCPSi films were immerged in 10 v-% 1,7-octadiyne–mesitylene solution at 150 C for 
16 h, adapting the thermal addition process described elsewhere.
187
 The THCPSi-alkyne 
NPs were obtained by wet-milling of THCPSi-alkyne film in a fresh 10 v-% octadiyne–
mesitylene solution and then centrifuged to obtain the required NP size. 
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4.2 Chemical modification  
4.2.1 Targeting peptides surface modification of APS-TCPSi NPs (I) 
The functionalization of targeting peptides onto the TCPSi NPs’s surface via SPAAC was 
achieved in two steps. Firstly, APS-TCPSi NPs were reacted with (1R,8S,9s)-
bicyclo[6.1.0]non-4-yn-9-ylmethyl succinimidyl carbonate (BCN-NHS) in 200 µL of 4-
(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer (0.1 M, pH 7.8) at 
room temperature to obtain click moiety decorated TCPSi-BCN NPs. Secondly, azide-
functionalized Arg-Gly-Asp-Ser (RGDS) and iRGD were reacted with TCPSi-BCN NPs 
via SPAAC in Milli-Q water at 37 C for 30 min. The TCPSi NPs were then harvested 
from the reaction mixture by centrifugation and washed with 1 mL ethanol/water three 
times to remove the unreacted peptides. 
For confocal fluorescence imaging and flow cytometry analyses, the APS-TCPSi NPs 
were first covalently labeled with fluorescein isothiocyanate isomer I (FITC). Briefly, 2 
mg of APS-TCPSi NPs were mixed with 0.1 mg of FITC in 400 μL ethanol and 100 μL 
0.1 M HEPES (pH 7.4). The FITC-labeled TCPSi NPs were continually reacted with 
BCN-NHS and the peptides as described above to obtain peptide-functionalized FITC-
labeled NPs. 
4.2.2 Multifunctional PSi NPs preparation (II) 
DBCO-PEG4-amine and Alexa Fluor
®
 488 (Life Technologies, USA) were conjugated to 
UnTHCPSi NPs via N-hydroxysuccinimide (NHS) and 1-ethyl-3-(3-
dimethylaminopropyl)-carbodiimide (EDC) coupling reaction to obtain UnTHCPSi-
Alexa488-DBCO NPs. 1,4,7,10-tetraazacyclododecane-N,N’,N’’,N’’’-tetraacetic acid 
(DOTA) and iRGD with azide moiety were sequentially conjugated to UnTHCPSi-
Alexa488-DBCO by the SPAAC reaction. 
For 
111
In-labeling of the multifunctional NPs, 1.251.5 mg UnTHCPSi-Alexa488-
DBCO-DOTA NPs were incubated with 178309 MBq of 111InCl3 at 85 C in 1.0 mL of 
0.1 M ammonium acetate buffer (pH 6.0) for 20 min. The peptide was conjugated to the 
NPs after 
111
In-labeling to achieve a multifunctional nanocarrier system. The NPs were 
formulated in sterile 0.9% NaCl solution to a concentration of 83 MBq/mL before 
injection. 
4.2.3 Surface modification of THCPSi-alkyne the NPs by CuAAC (III) 
The azide-functionalized compounds (RGDS, iRGD, and dextran of MW 6 kDa and 40 
kDa) were dissolved in anhydrous dimethyl sulfoxide (DMSO) and poly(glutamic acid) 
(PGA) was dissolved in Milli-Q water. The azide-functionalized reagents were added to 
the THCPSi-alkyne NPs, with copper (II) sulfate pentahydrate and sodium ascorbate, and 
all stirred at room temperature protected from the light for 24 h. After reaction, the NPs 
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were collected from the reaction mixture by centrifugation, washed with 
DMSO/ethanol/water, and re-suspended in ethanol for further use. 
4.2.4 Peptide-oligonucletide conjugation (IV) 
Linear iRGD and other peptides (H-RN, C16Y, and ATW) targeting to neovasculature 
were prepared through the standard Fmoc-chemistry solid support peptide synthesis 
(SPPA) by an automated peptide synthesizer. iRGD was prepared by cyclization through a 
disulfide bond presented in cysteine of linear iRGD. The amino acid containing azide 
functional group was induced to the N-terminal of iRGD in order to keep the CendR 
property of iRGD,
266
 and to the C-terminal for all the other peptides during the SPPS 
synthesis. Alkyne terminated oligonucleotide antisense interleukin-6 (ASIL-6-Alkyne) 
and fluorescent labeled ASIL-6 were synthesized by an automated DNA synthesizer on a 
400 nM scale. 
Azide functionalized targeting peptides and ASIL-6-alkyne were conjugated in 
water/formamide solution by CuAAC. Briefly, ASIL-6-Alkyne (10 nmol) in Milli-Q water 
was added to the peptide (100 nmol) in 250 μL formamide, following the “click solution” 
(1 μmol CuSO4, 1 μL sodium ascorbate, and 2 μmol μmol tris(benzyltriazolyl-
methyl)amine (TBTA) in 40 μL DMSO/tert-butyl alcohol 3:1) added. The reaction 
mixture was mixed at room temperature overnight and the conjugated products were 
purified by HPLC and confirmed by mass spectrometer (MS). More detailed information 
about the techniques used in this work is presented in the publication (IV). 
4.2.5 Conjugation of MTX to the APS-TCPSi NPs (V) 
MTX was conjugated to the amine-terminated PSi (APS-TCPSi) NPs using NHS/EDC 
coupling reaction. The conjugated PSi NPs was separated from the reaction mixture and 
washed by 1 mL of DMSO/water/ethanol three times to obtain the MTX conjugated PSi 
NPs (MTXPSi), which were then re-suspended in ethanol for further use. 
4.3 Physicochemical characterization (I–V) 
The surface area, pore volume, and pore diameter of the prepared PSi NPs were 
determined by N2 sorption at 77 K using TriStar 3000. The specific surface area of the PSi 
NPs was calculated using the Brunauer-Emmett-Teller theory.
267
 The total pore volume 
was obtained as the total adsorbed amount at a relative pressure p/p0 = 0.97. The average 
pore diameter was calculated from the obtained surface area and pore volume by assuming 
the pores as cylindrical (I–III, and V). 
The chemical surface modification of the PSi was characterized by Fourier transform 
infrared spectroscopy (FTIR) (I–III, and V), elemental analysis (EA) (I and V) and 
thermal gravimetric (TG) analysis (III). The size and zeta-potential of the NPs prepared 
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were measured by dynamic light scanning (DLS) (I–III, and V). The morphology of the 
NPs was determined by a transmission electron microscopy (TEM), JEM-1400, using a 
voltage of 80 kV and magnifications between 250 and 50000 (III and V). The peptide-
oligonucleotide (including fluorescent labeled ASIL-6) conjugates were confirmed by MS 
(IV). 
4.4 Drug loading and release 
4.4.1 Sorafenib loading and release studies (I, II, and V) 
The poorly water-soluble antiangiogenic drug, sorafenib, was used as model compound to 
test the physical adsorption of the loaded drug and its release profiles from the surface of 
the modified NPs. The chemotherapeutic drug, MTX, was chemically conjugated to APS-
TCPSi NPs (see section 4.1.4). Sorafenib was loaded to the NPs using an immersion 
method. Sorafenib was dissolved in acetone (15 mg/mL, I and V) or dimethylformamide 
(DMF) (50 mg/ml,), and the drug/NP ratio used was 15:1 (w/w) (II). 
The drug loading degrees of the drugs were determined by immersing 200 μg of the 
drug-loaded NPs to 1 mL of acetonitrile/water mixture (42:58%, v/v) under vigorous 
stirring for 1 h and the supernatant was analyzed by high pressure liquid chromatography 
(HPLC) with the mobile phase of 0.2% trifluoroacetic acid (pH 2) and acetonitrile at a 
ratio of 42:58% (v/v) with a 1.0 mL/min flow rate and UV detector set at the wavelength 
of 254 nm. 
The drug release tests were performed in sink conditions using a shaking method.
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The release media used were cell culture medium with/without FBS (I), 10 mM of 2-(N-
morpholino)ethanesulfonic acid (MES, pH 5.5) with/without 10% FBS (I, II, and V) and 
10 mM HEPES (pH 7.4) with/without 10% FBS (I, II, and V). 
4.4.2 MTX release analysis (V) 
The MTX release was determined in sink conditions using a shaking method. The release 
media used were 10 mM MES (pH 5.5) and 10 mM HEPES (pH 7.4) with/without 10% 
FBS. The released MTX fragment from the MTXPSi NPs was confirmed by mass 
spectrometer. The amount of the released MTX vs. time was quantified by HPLC. The 
chromatographic separation was achieved using a Zorbax C18 (4.6 × 100 mm, 5 μm) 
column with the mobile phase consisting of 90% of aqueous phase (0.1 M of citric acid 
and 0.2 M of Na2HPO4 mixed at a ratio of 2:1, pH 6.0) and 10% of acetonitrile with flow 
rate of 1 mL/min with a UV detector set at the wavelength of 302 nm. 
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4.5 Plasma interaction and identification 
4.5.1 Human plasmaNP interaction studies (I) 
The size and zeta-potential of the PSi NPs during exposure to human plasma were studied 
by incubation of the NPs with human plasma at 37 C during 2 h. Anonymous donor 
plasma was supplied by the Finnish Red Cross Blood Service under the permission from 
the respective institutional ethical committee.  
4.5.2 Identification of plasma proteins associated with the PSi NPs (III) 
In paper III, the plasma proteins associated to the NPs with different surface 
modifications were identified. After the NPs incubation with human plasma at 37 C for 2 
h, the proteins associated with the NP samples were separated by sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE). The whole set of protein bands from the 
THCPSi-RGDS NPs were excised, alongside with the possible protein bands from all the 
other samples to verify the presence of complement C3 and its derivatives. The excised 
bands were digested and the peptides obtained by digestion were analyzed by MS. The 
proteins were identified from peptide mass fingerprint data with MASCOT search engine 
(v1.6b25 http://www.matrixscience.com). 
4.6 In vitro assays (I–III, and V) 
Endothelial EA.hy926 (ATCC, USA), U87 MG and PC3-MM2 cells were cultured 
according to the standard protocols described in the publications. 
4.6.1 Cell viability studies (I–III, and V) 
The in vitro cytotoxicity of the NPs was determined by an ATP-based cell viability kit 
following the manufacturer’s protocol, as described elsewhere.160 Briefly, cells were 
seeded in 96-well plates at the density of (1.0–1.5) ×104 cells/well and allowed to attach 
overnight. Then, the cell culture medium was replaced by 100 μL of medium (with or 
without 10% FBS) containing different concentrations of NPs. After predetermined 
incubation times, the number of living cells was determined based on the amount of ATP 
produced by the cells. Each experiment was performed at least in triplicate. Cells cultured 
in growth medium without NPs or with 1% of Triton X-100 served as positive and 
negative controls, respectively. The luminescence was measured with a Varioskan Flash 
fluorometer. The in vitro inhibition of cancer cell growth by the drug loaded into the NPs 
was also evaluated using the same cell viability assay and conditions, as described above. 
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4.6.2 Cellular uptake studies (I, III, and V) 
Confocal fluorescence microscopy (I), flow cutometry analysis (I), and TEM experiments 
(I, III and V) were used to evaluate the cellular uptake of the NPs. In confocal 
fluorescence microscopy assay, about 200 μL of 8×104 cells/well were seeded in Lab-
Tek

 chamber slides (Thermo Fisher Scientific, USA) one day before the experiment. The 
NPs were incubated with cells for 3 h. The NPs suspension was removed and the cells 
were rinsed three times with HBSS (pH 7.4). The cell membranes were stained with 
CellMask
TM
 Orange according to the manufacturer’s protocol, followed by cell fixation 
with 2.5% glutaraldehyde. Confocal images were taken with a Leica SP5 inverted 
confocal microscope, equipped with argon (488 nm) and DPSS (561 nm) lasers and HCX 
Plan Apochromate 63/1.2-0.6 water immersion objective. 
For flow cytometry, 1 mL of 2×10
5
 cells/well was seeded in 12-well plates. After 
reaching 80% confluency, the culture medium was replaced with a medium containing 
different concentrations of each NP and incubated with the cells for 3 h. After removing 
the NP solutions and washing the cells three times with HBSS (pH 7.4), to remove non-
adherent NPs, the cells were harvested by trypsin-ethylenediaminetetraacetic acid (EDTA) 
and treated with trypan blue (0.04% v/v) to quench the fluorescence of possible surface 
adherent NPs. Flow cytometry was performed with an LSR II flow cytometer with laser 
excitation wavelength of 488 nm using a FACSDiva software. About 10,000 events were 
collected for each sample and the data was analyzed using the Flowjo 7.6 software. 
The cellNP interactions of non-fluorescence labeled NPs were studied in vitro by 
TEM. About 2 mL/well of 5–6 × 105 cells/well were seeded in 6-well plates containing 
18×18 mm cover slip in each well. After overnight attachment, the medium was replaced 
by new medium containing each NP. After 2 to 3 h of incubation, the NPs’ suspensions 
were removed and the cells were washed three times with HBSS (pH 7.4) and fixed by 2.5% 
glutaraldehyde. Ultrathin sections of both control and exposed cells to the NPs were 
prepared, as described in detail in each publication. The TEM images were examined as 
described in section 4.3. 
4.6.3 Cell apoptosis (V) 
MTX causes cell death by inhibiting the activity of DHFR, and thus, inhibiting the DNA 
biosynthesis. In order to confirm the bioactivity of the released MTX fragments from the 
MTX-conjugated PSi NPs, 7-amino-actinomycin D (7-AAD) labeling DNA fragmentation 
programmed cell death experiments were performed by flow cytometry analysis. Briefly, 
2×10
5
 cells/mL/well of each cell was seeded in 12-well plates separately. After overnight 
incubation, the medium was replaced by new medium containing certain concentrations of 
the NPs for 24 h incubation. After removing the NPs’ solutions and washing the cells 
three times with HBSS (pH 7.4) to remove non-adherent NPs, the cells were harvested by 
trypsin-EDTA and kept on ice. Cells were then re-suspended in 100 μL BioLegand’s cell 
staining buffer and 5 μL of 7-AAD (50 μg/mL) was added to each sample and incubated 
for 15 min at room temperature in the dark. After that, 400 µL of HBSS buffer was added 
and the samples were analyzed by flow cytometry as descripted in section 4.5.4. 
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4.7 In vivo assays (II) 
4.7.1 Animal model 
Animal experiments were carried out in accordance to the European Union and Finnish 
national legislation and guidelines for animal experimentation. Subcutaneous xenograft 
tumor model was established by injections of 5×10
6
 prostate cancer cells PC3-MM2 in 50 
L DMEM into each of the bilateral flanks of male Hsd:NMRI-Foxnlnu/nu nude mice 
(68 weeks of age from Harlan) under isoflurane anesthesia. Tumors were allowed to 
develop for 8 days prior the studies and the mice were randomized into the imaging and 
therapy study groups (n = 3–4/group). The NPs and drug administration were performed 
under the isoflurane anesthesia. Intravenous injections were given in a volume of 120 L 
via a temporary catheter followed by a flush of the catheter with 0.1 mL of sterile 0.9% 
NaCl. Intratumoral administration was performed with a U100 insulin syringe and a 30G 
needle in a volume of 50 L/tumor. 
4.7.2 SPECT/CT imag 
ing and biodistribution 
The in vivo biodistribution of the tested 
111
In-radiolabeled multifunctional nanocarriers 
was assayed by using the small animal nanoSPECT/CT system. The whole-body 
SPECT/CT images were acquired under isoflurane anesthesia at 5 min after intravenous or 
intratumoral injections for 60 min (in dynamic scanning mode with 20 min frames and 16 
projections at 90 s per projection), and again at 26 h after administration (16 projections 
and 225 s per projection). The CT images were taken using 45 or 55 kV X-ray source, 500 
ms exposure time in 180 projections, pitch 0.5 with an acquisition time of 5 min after the 
respective SPECT scan. All images were reconstructed with HiSPECT NG software and 
analyzed using InVivo Scope software. 
After the last scan (27 h after administration), the mice were sacrificed and the samples 
of blood, urine, liver, spleen, lung, heart, kidney, skeletal muscle, lymph node (inguinal), 
bone, and tumor were collected for independent radioactivity measurements using an 
automated γ-counter. In addition, a 3-μL blood sample for radioactivity measurement was 
obtained after the first SPECT/CT scan (at 65 min post-administration) by venipuncture of 
the saphenous vein. 
4.7.3 Anti-tumor effect 
The drug delivery efficiency to inhibit the tumor growth of the developed NPs was 
evaluated. Sorafenib was used as the model therapeutic agent in this study. The animals 
received two repeated doses of sorafenib-loaded NPs (3 mg/kg of sorafenib) 24 h apart, on 
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days 9 and 10 after the tumor inoculation. Tumor growth was monitored every other day 
after the tumor inoculation throughout the study by digital caliper measurements and the 
approximate tumor volume was calculated using the formula, V (mm
3
) = [(/6)(ab)3/2], 
where a and b are the values of the two perpendicular measurements of the tumor, length 
and width, respectively. The detailed information about size of the tumor at the initiation 
of therapy was provided in publication (II). The animals were euthanized when any of the 
diameters reached the maximum upper limit of 1.0 cm. 
4.8 Ex vivo assays (II) 
Immunofluorescence staining was used to determine the long-term biodistribution of the 
prepared multifunctional nanocarriers. The liver, spleen, lung, kidney, heart, and tumors 
were collected and snap-frozen in liquid N2 for ex vivo assays. The tissues were sectioned 
to 5 and 10-m thickness and the sections were thaw-mounted on SuperFrost Plus 
microscope slides. For visualizing the blood vasculature, the tumor samples were stained 
with rat anti-mouse CD31 antibody followed by Alexa Fluor
®
 594-labeled anti-rat 
secondary antibody. The tumor cell surface expression of integrin ανβ3 was visualized 
using a hamster anti-mouse CD61 antibody followed by Texas Red-labeled anti-hamster 
secondary antibody. The nuclei were counterstained with 4',6-diamidino-2-phenylindole 
(DAPI). The stained sections of the tumors were imaged using a Leica SP5 inverted 
confocal microscope and the data was collected and analyzed by Leica LAS AF Lite 
software. 
Hematoxylin and eosin (H&E) staining was performed to analyze the biocompatibility 
of the multifunctional PSi and PSi-iRGD NPs and the tumor pathology after treatment. 
The slides were observed and photographed by an optical microscope (Leica DM LB 
research microscope). Histopathological assessment of the tissue samples was also 
performed for the H&E stained sections by a veterinary pathologist. 
4.9 Statistical analysis (I–V) 
Results of the assays were presented as mean ± standard deviation (s.d.) of at least three 
independent experiments. Student’s t-test (I–V) and a non-parametric Kruskall-Wallis test 
(II) were used to evaluate the statistical significance when applicable and set at 
probabilities of *p < 0.05, **p < 0.01 and ***p < 0.001 using Origin 8.6 and GraphPad 
Prism 6 softwares, respectively. 
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5. Results and discussion 
Chemical approaches can be employed to modify the surface of nanocarriers in order to 
improve the bioactivity of the drug delivery carriers for biomedical applications, as well as 
to prepare drug conjugates to overcome the limitations of certain drugs. Nanocarriers for 
targeting cancer drug delivery aim at increasing the drug delivery efficiency into the 
cancer tissue by the introduction of the targeting moieties onto the nanocarriers’ surface, 
which can specifically increase the nanocarriercancer tissue interactions. 
In this context, the effect of the surface modification of PSi NPs with targeting 
peptides was studied on the cellular uptake, drug delivery and the in vitro and in vivo 
behavior of these NPs. For intravenous drug administration, the plasma protein association 
to the nanocarrier can dramatically affect the biofate of the nanocarriers. Therefore, the 
protein adsorption onto the PSi NPs modified with targeting peptides and anti-fouling 
polymers was also studied. Furthermore, targeting peptides conjugated to oligonucleotides 
and drug-conjugated PSi NPs for combination cancer therapy were studied. 
5.1 Enhancing the cellular uptake by targeting peptide-
functionalized PSi NPs (I) 
RGD has been identified to have high affinity to integrins expressed by the nonvascular 
endothelial cells and tumor cells.
243, 268
 RGDS and iRGD are two derivatives of the 
targeting peptide RGD. In this study, RGDS and iRGD were conjugated to BCN-modified 
PSi NPs via SPAAC click chemistry. The cellular internalization efficiency, together with 
drug loading and drug dissolution profiles of the modified PSi NPs were evaluated. 
5.1.1 Surface functionalization of the PSi NPs by targeting peptides  
RGDS is a linear peptide, while iRGD is a cyclized peptide, which also presents tumor 
tissue penetrating properties.
266
 In this study, both the linear and cyclized peptides were 
chosen to study the surface conjugation ratio of the peptides to the PSi NPs, as well as to 
further evaluate the cellular interaction effect of the modified NPs with cancer cells. 
SPAAC click moiety BCN was introduced to the amine-terminated PSi NPs prior to the 
peptide biofunctionalization. Azide-functionalized RGDS and iRGD were conjugated to 
the BCN-modified PSi (APS-TCPSi) NPs via SPAAC click reaction (Scheme 1). The 
conjugation ratios to the amine functional group were 15.2% and 3.4% (molar ratios to the 
amine functional groups of APS-TCPSi) for RGDS and iRGD, respectively. The 
conjugated ratio was calculated based on the elemental analysis, which determines the 
percentage of each element in the samples. The increasing weight on hydrogen, nitrogen 
and carbon in the samples before and after conjugation were used for calculation. The 
lower conjugation ratio of TCPSi-iRGD was probably due to the ring structure of iRGD, 
which presented higher “steric hindrance” on the surface of the NPs. In the confocal 
imaging and flow cytometry experiments, the APS-TCPSi NPs were first covalently 
labeled with FITC before the peptides conjugation. Covalent labeling and peptides 
modifications produced a robust nanosystem for further drug loading and delivery studies. 
The size and zeta-potential of the modified NPs are presented in Table 3. 
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Scheme 1. Chemical conjugation of the peptides RGDS and iRGD to APS-TCPSi. BCN-NHS was 
reacted with the amine groups of APS-TCPSi NPs at pH 7.8 in order to obtain a 
SPAAC click moiety decorated TCPSi-BCN NP. Next, RGDS and iRGD were 
conjugated to the NPs via SPAAC in order to obtain TCPSi-RGDS and TCPSi-iRGD 
NPs. The chemical structure of the model drug sorafenib is also presented. Copyright 
© (2014) ElsevierB.V. Reprinted with permission from publication (I). 
Table 3. The size, polydispersity index (PDI), zeta-potential and drug loading degree of sorafenib 
by APS-TCPSi, TCPSi-RGDS and TCPSi-iRGD NPs. Copyright © (2014) Elsevier 
B.V. Reprinted with permission from publication (I). 
NP Size (nm) PDI 
Zeta-potential 
(mV) 
Drug loading 
degree (w-%) 
APS-TCPSi 165.6 ± 1.1 0.08 ± 0.02 35.1 ± 0.8 6.06 ± 0.65 
TCPSi-RGDS 179.6 ± 1.2 0.08 ± 0.01 11.3 ± 0.4 6.12 ± 0.87 
TCPSi-iRGD 188.8 ± 6.9 0.13 ± 0.04 11.2 ± 0.8 5.64 ± 0.56 
5.1.2 Cellular uptake of the NPs 
The cellular uptake of the peptide-modified NPs was evaluated in hybrid endothelial 
EA.hy926 cells using confocal and flow cytometry measurements (Figure 7). Both the 
RGDS and iRGD surface modifications of the PSi NPs enhanced the cellular uptake of the 
NPs compared to the unmodified APS-TCPSi. Furthermore, there were more TCPSi-
RGDS NPs located in the cytoplasm than TCPSi-iRGD, as observed in confocal and flow 
cytometry analyses. Both the peptide-modified PSi NPs showed similar size and zeta-
potential. The difference on the cellular uptake was probably due to the surface 
modification ratio (15.2% vs. 3.4%). A higher content of the peptide on the surface of the 
PSi NPs resulted in a better cellNP interaction, and thus, improved the cell 
internalization in vitro. 
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Figure 7. Cell uptake analysis of APS-TCPSi, TCPSi-RGDS and TCPSi-iRGD incubated with 
EA.hy926 cells for 3 h. (A) Confocal fluorescence microscopy images of EAhy.926 
cells. The NPs were covalently labeled with FITC (green) and the cell membrane was 
stained with CellMask (red). Scale bars are 10 µm. (B) Flow cytometry histogram 
graphics of the NPs at concentrations of 250 µg/mL. (C) Flow cytometry quantitative 
determination for the internalized NPs. Error bars represent s.d. (n  2). The level of 
the significant differences of the treated NPs was set at probabilities of *p < 0.05 and 
**p < 0.01. Copyright © (2014) Elsevier B.V. Reprinted with permission from 
publication (I).  
5.1.3 Drug loading and release 
Hydrophobic drug sorafenib was used as a model drug to study the drug loading and drug 
dissolution profiles of the surface-modified PSi NPs. The loading degree of each NP is 
listed in Table 3. The surface modification of APS-TCPSi by RGDS and iRGD did not 
significantly affect the drug loading capacity of the PSi NPs. 
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Figure 8. Dissolution profiles of sorafenib loaded in APS-TCPSi, TCPSi-RGDS, TCPSi-iRGD in 
different aqueous media. Bulk sorafenib in DMEM with and without 10% FBS (A), 
sorafenib loaded in the NPs in DMEM without (B) and with (C) 10% FBS, in buffer 
solution with 10% FBS at pH 7.4 (D) and pH 5.5 (E), and in DMEM without FBS 
(gray symbols) or with addition of 10% FBS (empty symbols) after 120 min (F). SF 
denotes for sorafenib. Copyright © (2014) Elsevier B.V. Reprinted with permission 
from publication (I). 
The drug release experiments were performed in the media with and without 10% FBS 
(Figure 8). Sorafenib is a very poorly water soluble drug, and no detectable sorafenib was 
observed when dissolved in the medium without FBS up to 1 week (168 h). About 14% 
(ca. 0.5 μg/mL) of free sorafenib was gradually dissolved in the medium contained 10% 
FBS during 1 week (Figure 8A). Sorafenib was also not dissolved from the NPs in the 
DMEM without FBS (Figure 8B). However, a fast release of sorafenib was observed from 
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the samples of the drug loaded in any of the three NPs in the media containing 10% FBS. 
About 69%, 70% and 79% of sorafenib was dissolved in DMEM with 10% FBS from 
APS-TCPSi, TCPSi-RGDS, and TCPSi-iRGD NPs, respectively, in the first 5 min 
(Figure 8C). The enhanced drug dissolution profiles were observed in the release media 
with 10% FBS at pH-values of 7.4 and 5.5 (Figure 8D, E). The effect of the FBS in terms 
of the release of sorafenib from the PSi NPs was further confirmed by adding 10% of FBS 
to the dissolution media 2 h later (Figure 8F). About 64%, 67% and 56% of sorafenib was 
dissolved in 5 min from the APS-TCPSi, TCPSi-RGDS, and TCPSi-iRGD NPs, 
respectively. By loading poorly-water soluble drugs to the PSi NPs, the drug dissolution 
rate was dramatically enhanced. The surface modification of the APS-TCPSi with either 
RGDS or iRGD did not comprise the drug release profiles of sorafenib. 
5.2 Multifunctional PSi NPs for cancer theranostics (II) 
Surface modification of the NPs with homing peptides can be used for cancer 
diagnostics.
202
 The accessibility to follow the fate of the developed nanovectors is also 
important in nanomedical research. A dual-labeled multifunctional system using 
carboxylic acid terminated PSi (UnTHCPSi) NPs was prepared for cancer theranostics. 
The radiolabeling of the NPs with 
111
In was used to monitor the biodistribution of the NPs 
using live SPECT/CT imaging. Alexa Fluor
®
 488 was covalently attached to the NPs for 
long-term biodistribution studies. The targeting peptide iRGD was introduced to the 
surface of the NPs via SPAAC to form a dual-labeled targeting peptide-functionalized 
theranostic PSi-based nanovector.
236, 269
 
5.2.1 Nanotheranostic PSi NPs preparation 
UnTHCPSi NPs were conjugated with Alexa Fluor
®
 488 and a SPAAC click moiety 
DBCO-PEG4-amine was introduced to the surface of the NPs using the NHS/EDC 
coupling reaction. Sequentially, azide-functionalized 1,4,7,10-tetraazacyclododecane-
N,N’,N’’,N’’’-tetraacetic acid (DOTA) and the targeting peptide iRGD was attached to the 
NPs using the SPAAC click reaction (Scheme 2). For the 
111
In-radiolabeled 
multifunctional NPs, the iRGD conjugation was done after the 
111
In-labeling. For 
simplicity, below the dual-labled UnTHCPSi NPs without/with iRGD are designated as 
UnTHCPSi-DOTA and UnTHCPSi-iRGD, respectively. 
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Scheme 2. Preparation of the multifunctional PSi theranostic nanovector. Reaction 1, NHS/EDC 
activates the carboxylic acid group on the UnTHCPSi NPs. Reactions 2 and 3, Alexa 
Fluor
®
 488 and DBCO-PEG4-amine are conjugated to the activated UnTHCPSi NPs, 
respectively. Reactions 4 and 6, DOTA and iRGD are conjugated to the NPs via 
SPAAC. In the case of the radiolabeling study, 
111
In-labeling was performed before 
the iRGD conjugation (reaction 5). Copyright © (2015) ElsevierB.V. Reprinted with 
permission from publication (II). 
5.2.2 In vivo SPECT/CT imaging and biodistribution studies 
Prostate cancer xenografted mice were used to study the in vivo biodistribution of the 
dual-labeled PSi NPs with/without iRGD modification. SPECT/CT was applied to 
evaluate the radiolabeling stability as well as to access the biodistribution of the 
radiolabeled NPs. After intravenous administration, both the NPs with/without iRGD 
modification were mainly accumulated in the liver and spleen, with no visible uptake of 
the NPs in the tumor by the SPECT/CT images (Figure 9A). During the first hour, minor 
radioactive signal was observed in the kidney for UnTHCPSi-DOTA NPs, followed by an 
increase in the radioactivity in the bladder. At 26 h time point, the radioactivity in the 
kidney was more evident for UnTHCPSi-DOTA NPs. This indicates the detachment of a 
small amount of 
111
In from the UnTHCPSi-DOTA NPs. For UnTHCPSi-iRGD NPs, a 
minor radioactive trace was observed in the bladder from the SPECT/CT imaging of the 
treated mice during the first hour, but no visible radioactivity in the bladder or in the 
kidney was observed at 26 h time point. This indicates that, except the minor impurity of 
the residual 
111
In left in the radio-labeled UnTHCPSi-iRGD sample, the 
111
In labeling in 
UnTHCPSi-iRGD NPs was more stable than in bare UnTHCPSi. In the case of 
intratumorally administered NPs, the radioactivity of both NPs was mainly found at the 
injection site in the tumor, as shown by the SPECT/CT images (Figure 9B). There was no 
significant change on the biodistribution of radioactivity in SPECT/CT imaging between 1 
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h and 26 h, which indicated that both the NPs were retained in the tumor after intratumoral 
administration. 
After 26 h of SPECT/CT imaging, the tumor samples were collected for quantitative γ-
counting analysis to determine the tumor accumulation of the NPs. Intravenously 
administrated iRGD-modified NPs achieved higher tumor specific accumulation compared 
to the NPs without iRGD modification, as judged from the tumor-to-muscle ratio of the 
radioactivity (Figure 9C). NPs surface modified by iRGD can increase the tumor 
accumulation of the nanocarriers.
241, 245
 In this study, after iRGD surface conjugation to 
the NPs, a higher tumor accumulation of the PSi NPs was achieved. Intratumoral 
administration of the nanocarriers can achieve a higher tumor-to-tissue ratio of the 
administered composites. In previous report, the elimination of the nanocarriers from the 
tumor is relatively fast and dependent on the properties of the nanocarriers in the case of 
intratumoral administration.
270
 In this study, 15.5 ± 2.0 ID% and 27.3 ± 9.3 ID% were 
remained in the tumor 27 h post injection (p.i.) for UnTHCPSi-DOTA and UnTHCPSi-
iRGD, respectively (Figure 9D). The iRGD surface modification rendered higher tumor 
retention of the NPs, but the difference was not statistically significant. Therefore, it is 
possible that the tumor retention of the NPs was slowed down due to the targeting peptide 
iRGD modification and increased interaction of PSi-iRGD NPs with the tumor cells. 
 
 
Figure 9. In vivo biodistribution and tumor accumulation studies after intravenous (A and C) and 
intratumoral (B and D) administration. (A) and (B) are Nano-SPECT/CT fused 
images of the whole body mouse. The images were taken in a dynamic mode during 1 
h at 5 min post-injection (p.i.) and at 26 h p.i. (C) and (D) are the quantitative γ-
counting analyses of the radioactivity in the tumor 27 h p.i.. Copyright © (2015) 
ElsevierB.V. Reprinted with permission from publication (II). 
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5.2.3 Ex vivo histological analysis 
The long-term tissue biodistribution of the NPs can be assessed by immunofluorescence 
staining of the tumor samples (Figure 10).  
 
 
Figure 10. Confocal images of the immunofluorescently stained tumor sections in mice after 
intravenous (A) and intratumoral (B) administration of the NPs. The images were 
taken from the middle of the tumor sections. The nuclei were stained with DAPI (blue). 
CD31 was visualized using antibodies pseudocolored in red. The NPs labeled with 
Alexa Fluor
®
 488 are shown in green. The merged images are presented in the last 
column (Scale bar: 500 μm). Copyright © (2015) ElsevierB.V. Reprinted with 
permission from publication (II). 
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Anti-CD31 antibody was used to visualize the blood vasculature of the tumor. By 
intravenous administration, more UnTHCPSi-iRGD NPs accumulated into the tumor 
section than UnTHCPSi-DOTA NPs, corroborating the idea that iRGD aided to promote 
the NPs deep penetration into the tumor stroma (Figure 10A).244 In the case of NPs 
intratumoral administration, both UnTHCPSi-DOTA and UnTHCPSi-iRGD NPs 
presented a concentrated mass on the injection site of the tumor section, which was in 
agreement with the SPECT/CT images, where the injected NPs were accumulated in the 
tumor (Figure 10B). 
5.2.4 Anticancer effect of the drug loaded in the multifunctional PSi NPs 
The inhibition of the tumor growth was used to assess the antitumor effect of the drug 
loaded in the prepared PSi nanovectors. Figure 11 shows the tumor growth curve 
presented as the ratio of the tumor size after the treatment compared to the initial tumor 
size before the treatment. By using two intravenous doses (24 h apart, each treatment 
corresponding to dose of 3 mg/kg of sorafenib), the sorafenib loaded in both the NPs 
suppressed similarly the tumor growth as the free sorafenib in DMSO-plasma solution 
(Figure 11A). This was probably due to the enhanced dissolution rate, and thus, the 
results of a fast release of sorafenib in the blood after administration by loading sorafenib 
into the UnTHCPSi-DOTA and UnTHCPSi-iRGD NPs.  
 
Figure 11. Inhibition of the tumor growth of PC3-MM2 xenografts in male nude mice by the 
treatment of sorafenib-loaded multifunctional PSi NPs. The data is represented as 
mean ± s.d. (n = 46). The statistical differences are UnTHCPSi-iRGD + SF vs. 
UnTHCPSiPSi-DOTA + SF vs. SF, p = 0.3238 (intravenous administration route, 
Kruskall-Wallis test) and p = 0.0107 (intratumoral administration route, Kruskall-
Wallis test). (i.v., intravenous; i.t., intratumoral; SF: sorafenib; p.i., post-injection). 
Copyright © (2015) ElsevierB.V. Reprinted with permission from publication (II). 
After intratumoral injection of two consecutive doses (24 h apart), sorafenib loaded in 
the UnTHCPSi-DOTA and UnTHCPSi-iRGD NPs presented higher inhibition effect of 
the tumor growth than the free sorafenib (Figure 11B). The tumor size of the mice 
increased ca. 10-fold in 20 days after the first treatment with sorafenib loaded NPs, while 
the tumor size increased ca. 50-fold in 16 days after the intratumoral treatment of free 
sorafenib solution. The fast elimination of small conventional drug molecules from the 
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tumor has been one of the obstacles for intratumoral administration of chemotherapeutic 
drugs.
222, 271
 The low effect of sorafenib by intratumoral administration was likely due to 
the fast pumping out of the drug molecules due to the high pressure in the tumor 
microenvironment.
222
 The PSi-based NPs were successfully retained in the tumor site with 
sorafenib. Due to the non-sink conditions in the tumor, the release of sorafenib was 
sustained from the NPs in the tumor tissue, and thus, inhibited the tumor growth. 
5.3 Effect of the surface modification of the PSi NPs on the 
cellular uptake and protein adsorption (III) 
The plasma protein association is the first biological barrier that the nanocarriers 
encounter after intravenous administration. Due to the high surface free energy, the plasma 
proteins adsorb onto the NPs and form protein corona immediately when in contact with 
the biological fluids.
272
 The material of the nanocomposite and the physicochemical 
properties of the NPs, such as hydrophobicity/hydrophilicity, charge, ionization and 
surface roughness, can affect the protein association.
272-273
 The widely studied hydrophilic 
PEG is one of the molecules used for the surface modification of NPs to prevent plasma 
protein adsorption,
247
 as well as to prevent complementary C3 protein activation.
274
 
However, the surface modification of the NPs with PEG do not benefit towards the tumor 
cell uptake.
220
 
In this study, targeting peptides and antifouling polymers were conjugated to PSi NPs 
and their effect on the cellular uptake and protein adsorption were evaluated. The THCPSi 
NPs are hydrophobic PSi NPs and have good stability in physiological conditions,
5
 thus 
alkyne-terminated THCPSi (THCPSi-alkyne) NPs were surface modified using click 
chemistry to incorporate bioactive molecules to the PSi NP’s surface. The targeting 
peptides (RGDS and iRGD) and antifouling polymers (poly(glutamic acid), PGA, MW 7k 
Da); dextran with MW of 6 kDa and 40 kDa) were chosen to be conjugated to the 
THCPSi-alkyne NPs using CuAAC. 
5.3.1 Surface modification of THCPSi-alkyne NPs 
The surface modification of the THCPSi-alkyne NPs by RGDS, iRGD, PGA, dextran 6 
kDa and 40 kDa was achieved by CuAAC (Scheme 3) at room temperature in mild 
conditions, as described in the experimental part. The reaction was monitored by FTIR 
and the conjugation ratio was determined by TG analysis (Table 4). The size and zeta-
potential of the NPs were determined by dynamic light scattering, as listed in Table 4. The 
size of the surface modified NPs increased gradually in consistence with the MW of the 
conjugated biomolecules. The zeta-potential of the NPs modified by RGDS, iRGD and 
PGA remained negative, because of the neutral charge of the RGDS and iRGD and 
negative charge of PGA in Milli-Q water. The dextran 6 kDa and 40 kDa surface 
modification of the THCPSi-alkyne NPs presented positive zeta-potential values. 
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Scheme 3. Chemical surface modification of THCPSi-alkyne by the peptides RGDS and iRGD, 
and the polymers PGA and dextran 6 kDa and 40kDa. Copyright © (2015) American 
Chemical Society. Reprinted with permission from publication (III). 
 
Table 4. The hydrodymanic size, PDI, zeta-potential and the conjugation ratio of the surface 
functionalized THCPSi-alkyne NPs. Copyright © (2015) American Chemical Society. 
Reprinted with permission from publication (III). 
NP Size (nm) PDI 
Zeta-potential 
(mV) 
Conjugation 
ratio
a
 
THCPSi-alkyne 176.3 ± 2.6 0.09 ± 0.01 20.4 ± 0.5  
THCPSi-RGDS 181.6 ± 2.2 0.07 ± 0.01 22.1 ± 1.0 2.35 ± 1.70 
THCPSi-iRGD 186.7 ± 1.1 0.06 ± 0.02 24.2 ± 0.5 5.83 ± 2.48 
THCPSi-PGA 180.9 ± 1.1 0.06 ± 0.02 31.6± 0.2 N.D.
b
 
THCPSi-Dex6k 200.5 ± 0.1 0.06 ± 0.02 +22.8 ± 0.3 2.62 ± 0.81 
THCPSi-Dex40k 221.9 ± 1.9 0.08 ± 0.01 +14.4 ± 0.6 4.93 ± 1.41 
a
Conjugation ratio presented as the mass percentage of the conjugated biomolecules to the whole 
modified NPs. 
b
N.D. = No
 
Data. TG analysis was inconclusive as the conjugated PGA did not decompose under 
the experimental conditions used. 
5.3.2 The cellular uptake of the modified PSi NPs 
Efficient cellular uptake is an important step for the drug carriers which need to deliver the 
drug into the cytosol. Previous work reported that THCPSi NPs display low cell uptake by 
Caco-2 cell monolayers and RAW264.7 macrophage cells 
160
. Here, the cellular uptake of 
the surface modified NPs was evaluated in hybrid endothelial EAhy.926 and brain cancer 
U87 MG cells (Figure 12). The surface modification by both targeting peptides (RGDS 
and iRGD) and polymers (PGA, dextran 6k and 40k) increased the cellular uptake of the 
NPs in the EAhy.926 and U87 MG cells. For EAhy.926 cells, the order for the cellular 
uptake efficacy was as following: THCPSi-RGDS ~ THCPSi-iRGD > THCPSi-Dex40k > 
THCPSi-Dex6k > THCPSi-PGA > THCPSi-alkyne. In U87 MG cells, the cellular uptake 
efficacy was in the following order: THCPSi-PGA > THCPSi-RGDS ~ THCPSi-
iRGD>THCPSi-Dex40k > THCPSi-Dex6k > THCPSi-alkyne. The targeting peptides 
RGDS and iRGD can specifically interact with the cell membrane’s receptor integrin ανβ3 
and increase the uptake of the conjugated cargo by integrin-expressing tumor cells.
275
 It 
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has been reported that dextran modified microparticles increased the hydrophilicity as well 
as also increased the particlecell interactions, and thus, enhanced the cellular uptake of 
the particles.
276
 PGA incorporated NPs can undergo γ-glutamyl transpeptidase receptor 
mediated cell uptake, and thus, enhance the cancer cell uptake.
277
 
 
Figure 12. TEM images of the intracellular distribution of the THCPSi-alkyne THCPSi-RGDS, 
THCPSi-iRGD, THCPSi-PGA, THCPSi-Dex6k and THCPSi-Dex40k NPs in 
EA.hy926 and U87 MG cells. Inset scale bars are 200 nm and the arrows indicate the 
sample of each type of THCPSi NPs. Copyright © (2015) American Chemical Society. 
Reprinted with permission from publication (III). 
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5.3.3 Plasma protein adsorption onto the PSi NPs 
The surface modification of the NPs by hydrophilic peptides and polymers can reduce the 
plasma protein association.
24, 202
 The plasma protein adsorption to the surface modified 
NPs was analyzed by SDS-PAGE and identified by MS (Figure 13). Unmodified 
THCPSi-alkyne (Figure 13, lane B) showed the highest tendency for protein adsorption. 
The THCPSi-Dex40k (Figure 13, lane G) displayed the least protein adsorption compared 
to all the other NPs, especially the protein in the high MW range 70200 kDa. THCPSi-
Dex6k (Figure 13, lane C) had more serum albumin adsorption compared to THCPSi-
Dex40k. THCPSi-PGA (Figure 13, lane F) had more protein adsorption than THCPSi-
Dex6k, but less than THCPSi-RGDS (Figure 13, lane D) or THCPSi-iRGD (Figure 13, 
lane E). The complement 3 (C3) protein is the major plasma protein involved in the inert 
immune recognition of exons in the plasma by macrophages.
278
 In this study, only both the 
peptide-modified NPs activated the C3 protein by adsorption of C3 protein and converting 
to C3a/b form. The activation of C3 protein will accelerate the MPS uptake. However, in a 
recent publication, monocytes were shown to be able to uptake and deliver the RGD-
modified SWNT to the tumor intersitium.
279 In the MW range of 35 ̶70 kDa of the 
adsorbed protein, the two dextran-modified NPs presented similar protein adsorption 
profiles, while the other four NPs had similar protein adsorption profiles. There was no 
adsorption of fibrinogen γ chain, and less adsorption of immunoglobulin G (IgG) heavy 
chain, fibrinogen γ chain, clusterin, and apolipoprotein E proteins to the both dextran 
modified NPs. The fibrinogen proteins and immunoglobulins, and complement proteins, 
are the major proteins that can induce the immune system phagocytosis.217 The protein 
clusterin is involved in cell apoptosis, complement mediated cell lysis and membrane 
recycling,280 and also inhibits the complement activity.281 Apolipoprotein E is a group of 
apolipoproteins that are involved in the hepatocytic elimination of certain type of NPs.282 
For the plasma proteins with MW below 35 kDa, all the NPs presented a similar protein 
association profile. 
 
Figure 13. SDS-PAGE analysis of the protein adsorption characteristics of the NPs. Lane A, the 
MW marker; Lane B, THCPSi-alkyne; Lane C, THCPSi-Dex6k; Lane D, THCPSi-
RGDS; Lane E, THCPSi-iRGD; Lane F, THCPSi-PGA; Lane G, THCPSi-Dex40k; 
and Lane H, the pure human plasma. Copyright © (2015) American Chemical Society. 
Reprinted with permission from publication (III). 
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The surface “steric repulsion” by hydrophilic polymers has been shown to prevent the 
plasma protein interaction.
283
 The surface modification of the NPs with different moieties, 
as compared to the same bare THCPSi-alkyne NPs, showed that the surface 
biofunctionalization affected the plasma protein association profiles. 
5.4 Targeting peptides conjugated to oligonucleotide (IV) 
Four peptides (iRGD, H-RN, C16Y and ATW) were chosen to study the reaction of 
peptide-conjugation with ASIL-6 by CuAAC. iRGD presented specific affinity to the cells 
overexpressing ανβ3 and ανβ5 integrins.244 H-RN is an 11-amino acid peptide derived 
from the hepatocyte growth factor kringle 1 domain, which can inhibit the angiogenesis in 
vitro and in vivo.
284
 Peptide C16Y can interact with ανβ3 and α5β1 integrins, which are 
presented in angiogenic cells and tumor cells.
285
 ATW peptide can selectively bind to 
vascular endothelial growth factor-2 (VEGFR-2).
286
 ASIL-6 conjugated with targeting 
peptides could be more efficiently delivered into the inflammatory angiogenic tissue to 
down-regulate the expression of IL-6 and further reduce the inflammation. 
The click moiety azide was functionalized to the N-terminal of iRGD and C-terminal 
of all the other peptides. Alkyne moiety was induced to either 3’- or 5’- end of the ASIL-6 
sequence. Both the peptides and oligonucleotides were separately synthesized through the 
standard protocol and purified by HPLC and further verified by MS (Tables 5 and 6). The 
peptide-oligonucleotide conjugation was performed in water/formamide solution using 
CuAAC (Scheme 4). The reverse-phase HPLC profiles of the (3’)ASIL-6-iRGD conjugate 
showed 2 min retention time shorter than the initial (3’)ASIL-6-alkyne, which might be 
due to the hydrophilicity of iRGD. The ASIL-6-iRGD conjugate became more hydrophilic 
than ASIL-alkyne. The conjugate was further confirmed by MS. Furthermore, (5’)ASIL-6-
alkyne and 5’-end fluorescent (6-FAM) labeled ASIL-6-alkyne (alkyne group at 3’-end) 
were successfully conjugated with iRGD in the same reaction manner (Table 6). The 
successful fluorescent labeling and iRGD conjugation can be very useful for further 
imaging and biosensor studies. These results demonstrate that CuAAC is robust to 
conjugate iRGD to ASIL-6 at both 3’ and 5’ termini, while other biofunctional molecules 
or labeling reagents can be introduced to the other terminal of the oligonucleotide 
sequence, which is very flexible way to tailor the properties of ASIL-6. 
 
Scheme 4. The conjugation of ASIL-6 –alkyne with azide functionalized peptides by CuAAC. 
Copper (II) was reduced to copper (I) by sodium ascorbate and tris(benzyltriazolyl-
methyl)amine (TBTA) used as copper (I)-stabilizer. Copyright © (2014) Bentham 
Science. Reprinted with permission from publication (IV). 
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Table 5. MS characterization of azide-modified peptides. Copyright © (2014) Bentham Science. 
Reprinted with permission from publication (IV). 
Peptide The unmodified 
sequence of peptide 
MW (Da) Purity (%) 
Calculated Experimental 
Linear iRGD-azide CRGDRGPDC 1089.1 1089.4 95% 
iRGD-azide CRGDRGPDC (C1-C9) 1087.1 1087.4 98% 
H-RN-azide RNPRGEEGGPW 1365.4 1365.7 92% 
C16Y-azide DFKLFAVYIKYR 1673.9 1673.8 91% 
ATW-azide ATWLPPR 951.0 951.5 92% 
 
Table 6. MS characterization of alkyne functionalized ASIL-6, and the peptides conjugates. 
Copyright © (2014) Bentham Science. Reprinted with permission from publication 
(IV). 
Sample 
MW (Da) 
Purity (%) 
Calculated Experimental 
ASIL-6-alkyne (3’ or 5’) 5034 5033 93% 
5’-FAM-ASIL-6-alkyne (3’) 5571 5570 95% 
ASIL-6-iRGD (3’ or 5’) 6121 6119 96% 
5’-FAM-ASIL-6-iRGD (3’) 6658 6656 96% 
ASIL-6-H-RN (5’) 6396 6397 91% 
 
In addition to the iRGD, three other azide-functionalized peptides were also performed 
the conjugation to (3’)ASIL-6-alkyne using CuAAC. Peptide H-RN was successfully 
conjugated to ASIL-6 (Table 6), while C16Y and ATW peptides were not reacting with 
(3’)ASIL-6-alkyne. It is not fully understood yet why the CuAAC reaction worked with 
iRGD and H-RN but not with C16Y or ATW in terms of conjugation to ASIL-6. By 
checking the molecular structure of these four peptides, the side chains buried in iRGD 
and H-RN were relatively more hydrophilic than those buried in C16Y and ATW. The 
hydrophobicity of the side chain might play a crucial role in oligonucleotide-peptide 
solution-phase conjugation. The chemical structure of the side chains should be carefully 
considered when a functional peptide was chosen to chemically react to an oligonucleotide. 
5.5 Dual-drug delivery by PSi NPs (V) 
The chemotherapeutic drug methotrexate (MTX) is a folic acid analogue.
287
 It induces cell 
death by inhibiting the activity of dihydrofolate reductase (DHFR) enzyme in the cytosol 
of the cells.
230
 MTX has specific affinity to the folate receptor (FR) and enters into the 
cells through FR-mediated cellular uptake pathway.
288
 FR has been over-expressed by 
many human malignancies.
289
 However, MTX had low cellular uptake by FR deficient 
cells.
15
 By chemical conjugation of MTX to the cationic carriers, an increase in the 
cellular uptake of MTX can be achieved.
232, 290-291
 In this study, MTX was conjugated to 
amine-terminated APS-TCPSi NPs to form MTX-TCPSi NPs. In addition, the MTX-
TCPSi NPs can be used to enhance the dissolution rate of poorly-water soluble drugs. 
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Therefore, antiangiogenic drug sorafenib was also used as a model compound physically 
loaded to the MTX-TCPSi conjugates. The covalent attachment of MTX and the 
simultaneous loading of sorafenib to MTX-TCPSi NPs, and their effect on the dissolution 
profiles of MTX and sorafenib, as well as the anti-proliferation and cell apoptosis of 
MTX-TCPSi were all evaluated here. 
5.5.1 MTX-TCPSi conjugation and characterization 
MTX was conjugated to the PSi NPs through the carboxylic acid group of MTX and the 
amine groups from the APS-TCPSi NPs to form an amide bond using the NHS/EDC 
coupling reaction (Scheme 5). The molecular structure of MTX is presented in Scheme 
5B. The reaction was monitored by FTIR and the quantitative conjugation ratio was 
determined by elemental analysis. About 8.4 ± 1.6 % (molar ratio) of the amine group 
from APS-TCPSi was reacted with MTX, which equaled to the mass ratio of 5 μg of MTX 
to 1 mg of NPs. In a previous study, it has been demonstrated that the aminosilane surface 
moiety of APS-TCPSi can be detached by hydrolysis from the NPs surface in an aqueous 
buffer.
8
 The released compound from MTX-TCPSi was analyzed by HPLC and MS. 
There was no free MTX released from the MTX-PSi NPs. Instead,; the detected 
compound was the protonated molecule ([M+H]
+
, m/z 556.2) with a Mw 555.2 g/mol, 
which matched to the MTX with a fragment of 3-aminopropylesilicic acid (Scheme 5D). 
This result confirmed the release of MTX by detachment of (3-
aminopropyl)trihydroxylsilane (Scheme 5C) from the MTX-TCPSi NPs, and then 
dehydrolyzed to the molecule presented in Scheme 5D. 
 
Scheme 5. (A) MTX-conjugated to APS-TCPSi by EDC/NHS coupling reaction to form MTX-
TCPSi NPs. (B) Molecular structure of MTX. (C) Released fragment from MTX-PSi 
NPs. (D) Dehydrate form containing MTX determined by MS. Copyright © (2015) 
ElsevierB.V. Reprinted with permission from publication (V). 
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5.5.2 Evaluation of the drug release and cell apoptosis of MTX-PSi NPs 
MTX inhibits the DHFR enzyme to stop the tetrahydrofolate synthesis, and thus, can 
cause cell death.
287
 It has been reported that the effect of MTX-dendrimer conjugate 
inhibition of the DHFR was comparatively less active than that of the free MTX, which 
resulted in the conclusion that only one MTX molecule on each dendrimer could bind to 
the DHFR enzyme.
292
 An in vivo study showed that MTX conjugated to a carrier via a 
biocleavable ester linker reached significantly higher anticancer effect than when 
 conjugated to the non-cleavable amide bond.
78
 Thus, the release of MTX from the 
conjugated cargos is a significant step to reach the pharmacological effect of MTX.  
Here, the release profiles of MTX and sorafenib was studied by HPLC (Figure 
14AC). MTX showed sustained released from the MTX-TCPSi NPs. A faster release 
profile was obtained at pH 7.4 than at pH 5.5, which was due to the faster hydrolyzation of 
the surface silane moiety at higher pH-values.
8
 The MTX release profiles of MTX-TCPSi 
NPs in buffer without FBS (Figure 14B) and from MTX-TCPSi loaded with sorafenib in 
buffer with FBS (Figure 14C) were similar to the release profiles of MTX-TCPSi in 
buffer with 10% FBS (Figure 14A). This showed that the cleavage of the saline moiety 
from the TCPSi NP surface was not affected by the serum protein or by the loading of 
sorafenib. Furthermore, after the loading of sorafenib to MTX-TCPSi NPs for 
combination therapy, the dissolution profiles of sorafenib (Figure 14DE) were enhanced 
as a same result of the loading into the PSi NPs. 
Moreover, MTX is known to induce cell death by disturbing the DNA synthesis. Thus, 
the programmed cell death by MTX-TCPSi conjugation was confirmed by DNA 
fragmentation assay accessed by 7-amino-actinomycin D (7-AAD) staining and flow 
cytometry analysis (Figure 14FG). The low FR-expressed cell line EA.hy926 and over-
expressing FR cell line U87 MG were used in this study. In both the cell lines, the MTX-
TCPSi caused higher DNA fragmentation at higher concentrations, while the APS-TCPSi 
NPs did not induce severe DNA fragmentation. These results demonstrated that MTX-PSi 
NPs were uptaken by both the cells and the biological activity of the released MTX was 
maintained. 
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Figure 14. MTX release from MTX-TCPSi in buffer containing 10% FBS (A), in buffer without 
FBS (B), and MTX released from sorafenib-loaded MTX-TCPSi NPs in buffer 
containing 10% FBS (C). SF dissolution from APS-TCPSi and MTX-TCPSi NPs in 
buffer (pH 7.4) containing 10% FBS (D), and free sorafenib dissolution profiles in 
buffer (pH 7.4) containing 10% FBS (E). MTX–PSi NPs induced programmed cell 
apoptosis in EA.hy926 (F) and U87 MG cells (G.). Copyright © (2015) ElsevierB.V. 
Reprinted with permission from publication (V). 
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6. Conclusions 
Chemical modifications can modulate the surface properties of NPs, which in turn can 
play an important role on the NPs used for biomedical applications due to the interactions 
of the NPs with the biological systems. Also, chemical conjugation used to prepare drug 
conjugates can bring new features to the drug molecules to achieve an efficient delivery. 
The surface modification of APS-TCPSi NPs with targeting peptides (RGDS and iRGD) 
was achieved by the highly selective and robust reaction of SPAAC click chemistry. The 
surface modification of the PSi NPs enhanced the cellular uptake in the hybrid endothelial 
cells. The drug loading capacity and the enhancement of the dissolution rate of sorafenib 
drug by the PSi NPs were not affected by the surface modifications performed on the NPs. 
Fluorescent- and radio-labeled, targeting peptide functionalized PSi NPs were prepared 
from UnTHCPSi NPs. The stability and accessibility of the radio-labeling of PSi NPs via 
DOTA-mediated chelating were verified by SPECT/CT imaging. The iRGD modification 
of the dual-labeled NPs improved the tumor accumulation as shown by the radioactivity 
counting measurements, and enhanced the NP tumor penetration as demonstrated by the 
ex vivo immunofluorescent imaging after intravenous administration. However, both non-
targeted and iRGD-targeted PSi NPs were rapidly cleared from the blood stream and 
accumulated in the liver and spleen. By local intratumoral delivery, both the NPs were 
retained at the injection site for extended periods of time. H&E staining results showed a 
good biocompatibility of the prepared multifunctional PSi NPs. 
Furthermore, the alkyne-terminated THCPSi NPs were modified with targeting 
peptides and anti-fouling polymers via CuAAC, and the effect on the cellular uptake and 
protein association were evaluated. Both the targeting peptides and anti-fouling polymers 
modified THCPSi-alkyne NPs enhanced the cellular uptake compared to the unmodified 
THCPSi-alkyne NPs. In addition, the uptake efficiency of the NPs by cancer cells was 
surface moiety-dependent. The associated proteins to the modified NPs were also varied 
due to the different surface moieties. Overall, dextran of 40 kDa with the highest MW 
modified THCPSi-akyne NPs presented the lowest protein adsorption tendency. 
Targeting peptides iRGD and H-RN were successfully conjugated to ASIL-6 through 
solution-phase CuAAC reaction for angiogenic anti-inflammation therapy. Moreover, dual 
drug delivery was achieved by chemically conjugating MTX to cationic charged APS-
TCPSi NPs and physically loading a poorly-water soluble drug, sorafenib. The dissolution 
rate of antiangiogenic drug sorafenib was enhanced, while the release of MTX from the 
APS-TCPSi NPs was sustained. The antiproliferation effect and the pharmacological 
activity of the conjugated MTX to low FR-expressing cells were improved. 
The enhancement of the dissolution rate of poorly-water soluble drugs is an advantage 
of the porous structure presented by PSi nanomaterials. This dissertation developed 
successfully biofunctionalization methods to increase the cell–NP interactions, labeling of 
the NPs for tracking and imaging, drug-conjugates synthesis, and evaluated the behavior 
of the modified PSi NPs for potential cancer drug delivery applications. On the other hand, 
the ideal cancer drug delivery formulation would enhance the accumulation of the 
delivered cargo to the targeted tumor sites and control the drug release to reach the 
maximum therapeutic effect to inhibit the tumor growth with the lowest side effect. There 
is more work need to be done to develop the PSi based nano-drug delivery system to meet 
the ideal criteria for clinical applications. 
Overall, the chemical modification and labeling methodologies of PSi NPs via click 
chemistry have been developed and their biological interactions in terms of potential 
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cancer therapy have been assessed in this dissertation. The surface chemical modification 
approaches are versatile for preparing advanced multifunctional nanomaterials for medical 
applications. 
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